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Abstract 
KINETIC AND THERMODYNAMIC STUDIES OF THROMBIN INHIBITORS 
By May Hamdy Abdel Aziz, Ph.D. 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy at Virginia Commonwealth University. 
Virginia Commonwealth University, 2013. 
Supervisor: UMESH R. DESAI, professor, department of medicinal chemistry. 
Sulfated low molecular weight lignins (LMWLs), CDSO3 and FDSO3, designed recently as 
macromolecular mimetics of heparin, were found to exhibit potent anticoagulant activity. Small 
molecules based on the same scaffold, SBD and SBT, showed promising thrombin inhibition. 
All studied molecules were found to allosterically inhibit thrombin as inferred from Michaelis-
Menten kinetics. Absence of competition with hirugen, an exosite 1 ligand, and competition 
with polymeric heparin points to exosite 2 as the site of interaction for these inhibitors. Site-
directed mutagenesis of all positively charged exosite 2 residues showed that Arg93 and 
Arg175 are the major residues involved in CDSO3 binding. FDSO3 showed a progressively 
greater defect in inhibition with double point mutations, the triple mutant Arg93,97,101Ala 
displayed a 50 fold drop in inhibition. A single mutant, Arg173Ala, displayed 22-fold reduction 
in IC50 of SBD, while Arg233Ala was the only mutation that impaired SBT inhibition. Salt-
dependence studies showed that CDSO3 had fewer ionic contacts with thrombin, with most of 
its binding energy derived from non-ionic interactions. FDSO3 on the other hand had a balanced 
xiii 
 
 
 
 
contribution of ionic and non-ionic forces. Thermodynamic studies showed that both polymers 
have a positive ΔCp of binding, which proves the involvement of electrostatic forces and 
signals the burial of the polar residues on thrombin exosite 2. The presence of sodium was 
found to enhance the binding of FDSO3 at exosite 2. The results identify novel binding sub-
sites within exosite 2 that are energetically coupled to thrombin’s catalytic function and linked 
to the sodium binding site. The design of high affinity small molecules based on LMWLs 
scaffold presents major opportunities for developing clinically relevant, allosteric modulators 
of thrombin. 
xiv 
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Chapter 1: Introduction 
1.1. Thrombin and the Coagulation Cascade 
Thrombin is a key serine protease that maintains blood hemostasis by balancing, 
seemingly antithetical, pro- and anti-coagulant actions. Hemostasis is maintained through the 
sequential activity of a group of enzymes and cofactors that constitute the coagulation cascade. 
This is a physiologically critical process of consecutive reactions for preventing excessive loss 
of blood after sustaining injury, but aberrant clot formation can result in life threatening 
thrombotic disorders such as pulmonary embolism, deep-vein thrombosis, myocardial 
infarction and unstable angina. More than a half million patients are diagnosed annually in the 
US for which the treatment of choice is anticoagulants with a global market estimated to reach 
$12 billion by 2015.1 Theoretically a drug could target one or more enzyme involved in the 
chain reaction in order to stop the clot formation, yet most of the developed agents are targeting 
thrombin and factor Xa (FXa).  
The cascade is mainly formed of three stages, initiation, amplification and propagation 
(Figure 1). This delicate process starts when tissue factor, a protein found on subendothelial 
cells that are shielded from circulating proteinases is exposed by an injury. After exposure it 
forms a complex with circulating factor VIIa (FVIIa) to generate factor IXa (FIXa) and factor 
Xa (FXa) at low levels.2,3 The latter forms a complex with factor Va (FVa), called the 
prothrombinase complex (FVa, FXa, Ca2+ and phospholipids), which in turn generates a small 
quantity of thrombin from its zymogen, prothrombin.  
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The second stage, called amplification, involves the small amount of the so produced 
thrombin acting as a procoagulant by activating factors XI, VIII and V. It also has a 
prothrombotic role as it reacts with protease-activated receptors (PARs) leading to platelet 
activation and aggregation at the site of injury and formation of a plug to prevent hemorrhage.4 
The activated factors initiate the last stage of the cascade, propagation, where factor VIIIa  
(FVIIIa) complexes with FIXa to form larger quantities of FXa which in turn is involved in 
formation of larger amounts of the prothrombinase complex that yields bulk quantities of 
thrombin. Activated platelets expose the fibrinogen receptor on their membrane, which attract 
and localize fibrinogen from the blood stream to the injury site. The produced thrombin acts as 
a procoagulant through its cleavage of fibrinogen to generate the fibrin monomers that self-
aggregate to form a loose network, which is the initial clot.5 This procoagulant role is 
substantiated by its activation of factor XIII (FXIII), which stabilizes the formed clot and 
thrombin-activatable fibrinolysis inhibitor (TAFI) that inhibits fibrinolysis.  
On the other hand, thrombin has another, seemingly contradictory, role through 
activation of protein C, a natural anticoagulant that cleaves and inactivates factors Va and 
VIIIa.6 Normally the affinity of thrombin for the zymogen protein C is low; it increases by a 
dramatic 1000-fold after binding to thrombomodulin, a receptor on the membrane of 
endothelial cells. The binding also decreases thrombin’s ability to cleave fibrinogen and PAR-
1.7,8 The delicate balance of pro- and anticoagulant activities has established thrombin as the 
most attractive target for study as well as for developing anticoagulant agents. 
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Physiologically, the inhibition of excessive coagulation is achieved by regulatory 
proteins such as antithrombin (AT), a serine protease inhibitor (SERPIN), that mainly targets 
thrombin, FXa, and FIXa,9 and to a less extent FVIIa and FXIa10-12 using the well-established 
“mousetrap” mechanism.13 The rate of AT inactivation is relatively slow under physiological 
conditions, but is greatly enhanced in presence of heparin, a glycosaminoglycan (GAG) 
polysaccharide that increases AT’s efficiency by 102 – 106 fold depending on the targeted 
protease.10 This forms the basis for the wide use of heparin as an anticoagulant since 1916.14 
Another natural inhibitor is tissue factor pathway inhibitor, which only targets FXa.15 
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1.2. Anticoagulants in Market 
Current treatment options for thrombotic disorders include either direct agents that act 
on one or more of the enzymes involved in the coagulation cascade or indirect agents that 
hamper these enzymes’ formation or activate their natural inhibitors. The indirect class contains 
the widely used heparins and vitamin K antagonists (VKAs).  Heparin and its variants, low-
molecular-weight heparins (LMWH) and fondaparinux (a modified pentasaccharide) induce 
their effect by activating AT which irreversibly inhibits several coagulation enzymes (Figure 
2A). VKAs inhibit necessary post translational modifications required for producing the fully 
functional proteases. VKAs are the only orally available anticoagulants and include warfarin, 
dicoumarol, acenocoumarol and phenprocoumon (Figure 2C).1  
The direct class of inhibitors mainly target thrombin and are thus called direct thrombin 
inhibitors (DTI). This includes the hirudins and the peptidomimetic inhibitors like ximelagatran 
and melagatran. A newer direct inhibitor drug developed to target FXa, rivaroxaban, was 
approved in 2008 in the European Union and Canada, and in 2011 in US markets (Figure 3). 
These agents have the advantage of possibly inhibiting both free and clot bound enzymes16-18 
and have specificity toward certain targets, which improve its safety profile as well as the 
likelihood of developing antidote to reverse their effects. Each of the currently used 
anticoagulants suffer from major adverse consequences. The agents also share the problem of 
non-oral availability and the higher risk of minor and major bleeds. Anticoagulants as a group 
ranked first in 2003 and 2004 in number of total deaths from drugs in therapeutic use.1 Beside 
this fatal side effect, each anticoagulant in the market suffer other serious complications 
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including hepatotoxicity, thrombocytopenia and immunogenicity. Discovering safer, orally 
available, specific and effective new molecules may dramatically alter the anticoagulation 
therapy of the future. 
Figure 2. Indirect anticoagulants, (A) Heparins, (B) Fondaparinux, and (C) VKAs that include 
warfarin, dicoumarol, acenocoumarol and phenprocoumon 
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Figure 3. Direct thrombin inhibitors, the peptidomimetics ximelagatran and melagatran and 
the small molecule recently approved in the market to target FXa, rivaroxaban. 
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1.3. Indirect Thrombin inhibitors and their Limitations 
Unfractionated heparin (UFH) is a linear polydisperse polysaccharide of ~15,000 Da 
molecular weight with phenomenal structural variability (Figure 2). The backbone is assembled 
by alternating 1→4-linked uronic acid and glucosamine residues. Sulfate and carboxylate 
groups decorate the polysaccharide backbone with a high density of ~3.7 negative 
charge/disaccharide. This makes the molecule the strongest acid in human bodies.1 The 
anticoagulant effect is an indirect one that arises through its interaction with antithrombin (AT), 
the primary physiological inhibitor of the coagulation cascade. 
The mechanism of antithrombin activation by the heparin chains involves two 
pathways. In one mechanism a specific sequence on the heparin chain that has high affinity for 
antithrombin, a pentasaccharide called DEFGH (KD = 50 nM)1, binds and induces a 
conformational change in AT that activates the serpin against its targets.19-21 This pathway is 
sufficient to induce full inhibition for FXa by accelerating the reaction by almost 300-fold in 
absence of calcium.9,10,22,23 The structure of synthetic fondaparinux and idraparinux is based 
on this sequence. The other pathway involves the full-length heparin chains (at least 18 
residues24-26) acting by bridging or template mechanism, which prevails in the case of 
antithrombin inhibition of thrombin.27 The same high affinity sequence binds to antithrombin, 
followed by non-specific binding of the protease to another part of the long heparin chain. 
Thrombin then diffuses along the polymer to interact with the serpin forming a ternary complex 
with 1000-4000 fold accelerated rate (Figure 4). The length of the chain required for this 
mechanism renders many LMWHs and pentasaccharide anticoagulants ineffective in 
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accelerating AT-thrombin inhibition. In the presence of calcium, heparin inhibition of FXa and 
FIXa proceeds via a combination of the two pathways. 
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The risks of bleeds with heparin are the highest in its class, yet it has a suitable antidote: 
protamine sulfate, a linear polymer with positively charged nitrogen groups that neutralize 
heparin’s negative charges. Beside this problem, heparin has the problem of intra- and inter-
patient variability, which requires close monitoring and dose adjustment. This is mainly 
attributed to the low selectivity of heparin, which binds to many targets, some of which are 
proteins that become elevated variably in pathological conditions, which reduces its efficacy. 
Heparin induced thrombocytopenia (HIT) is another fatal adverse reaction of heparin, where 
the platelet count drops between 4 to 14 days after beginning treatment, and osteoporosis 
associated with chronic usage.29 A serious allergic reaction was reported in 2007 following 
heparin administration that resulted in at least 81 reported deaths, the symptoms included 
hypotension, nausea, vomiting, diarrhea and abdominal pain. The samples were discovered to 
be contaminated with up to 30% of oversulfated chondroitin sulfate (OSCS).1 
The problem is more complicated with regard to clot-bound thrombin. Heparin is 
incapable of binding to it and thus, this form of thrombin is resistant to inhibition by 
antithrombin rendering the patients susceptible to the restart of clotting.14,16-18 The molecular 
dissection of the interaction revealed that the thrombin on the clot surface is bound to γ’ chain 
of fibrin via its exosite 2, the same binding site as heparin. Thus, it competes with heparin 
chains for binding and hampers antithrombin inactivation.30-32 The γ’ fibrin(ogen) peptide is a 
useful tool, like heparin, as a natural ligand that binds to exosite 2 of thrombin.  
Low molecular weight heparin (LMWH) is a smaller version (MR 5,000 Da) with lower 
polyanionic charges created by chemical or enzymatic depolymerization of heparin.22 It has the 
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advantage of higher bioavailability and longer duration of action (12 h)1 along with lower 
occurrence of bleeding and less patient variability.33,34 Unfortunately the efficacy of protamine 
as an antidote is only partial, unlike that of heparin. This could be due to the fact that it is more 
efficient in neutralizing long polymeric chains.1 
Other smaller versions of heparin include the pentasaccharide fondaparinux, which is a 
highly specific sequence (DEFGH) in heparin that interact with antithrombin, lacks HIT and 
has predictable patient response.35 On the other side of the coin, protamine sulfate is completely 
useless for reversal of fondaparinux toxicity, so in the event of a major hemorrhage there is no 
current antidote.33,36 Another pentasaccharide developed is idraparinux, which has a long 
duration requiring only once a week injections. Owing to its structural similarity with 
fondaparinux, it is probably going to share its side effects.37,38 Clinical trials using idraparinux 
were stopped due to the increased risk of bleeding.39 A biotinylated version (SSR126517E) is 
being developed, since it could be neutralized by injecting avidin.40 
1.4. Direct Thrombin Inhibitors and their Limitations 
DTIs include agents that target the active site and/or exosite 1 of thrombin and work 
through either competitive or mixed-type inhibition mechanism to reduce the enzyme catalytic 
activity. This class includes hirudin and its analogues, which are extremely potent peptides 
derived from the leech hirudo medicinalis. These induce major bleeding episodes with no 
effective antidote.41 Its peptidic nature causes the formation of antibodies that seem to delay its 
clearance, thus increasing its efficacy.42 This heightened potency (20 fM for hirudin) renders 
the inhibition almost irreversible.  
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Two other analogues derived from hirudin are also available, lepirudin and desirudin, 
which lack the sulfate group at Y63 of hirudin and contain two residues at the N-terminus of 
hirudin substituted with Leu-Thr and Val-Val, respectively. A smaller version that belong to the 
same class of “hirulogs” is bivalirudin, which was developed with lower potency (1-2 nM) and 
shorter half-life. It has the advantage of lower immunological reactions and more predictable 
response. The only designed peptidomimetic to reach the market is argatroban, but its usage is 
limited by short life in plasma.1 To address the oral bioavailability challenge another agent was 
developed, ximelagatran, which acts as a pro-drug for melagatran. It was approved in Europe, 
but the US FDA did not approve it because of hepatotoxicity reports.43 It was withdrawn from 
European markets due to several cases of liver failure.44 Another agent, dabigatran etexilate, 
was the only approved orally available DTI in US market (Figure 5).1,45 It was soon joined in 
2011 by rivaroxaban, which is a fXa direct inhibitor. 
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1.5. Exosite 2 Ligands and New Opportunities 
Exclusive natural exosite 2 ligands, e.g., GAGs, do not affect the catalytic activity of 
thrombin, although its binding does affect the thrombin active site as monitored by active site 
inhibited labeled enzyme. Thus, GAGs do not function as DTIs.46,47 Recently, low molecular 
weight lignins (LMWLs) were designed in our lab by chemo-enzymatic synthesis as heparin 
mimetics. In LMWLs a hydrophobic backbone is decorated by sulfate and carboxylate groups 
(Figure 6). Despite the fact that they structurally resemble heparin, which were able to directly 
inhibit thrombin in an antithrombin-independent manner, unlike heparin that requires the 
presence of the serpin for inhibition.27 These molecules proved in initial studies to be the only 
macromolecules to reduce significantly the kCAT of small chromogenic substrates by binding 
in or near exosite 2.48,49  
Three polymers were synthesized CDSO3, FDSO3, and SDSO3 from the corresponding 
4-hydroxycinnamic acid monomers, caffeic acid (CA), ferulic acid (FA), or sinapic acid (SA). 
Two types of common linkages present in the sulfated molecules include the β-O-4 and β-5 
linkages (Figure 7). The concept of the design was aiming to achieve binding at exosite 2 using 
the same recognition elements utilized by heparin, i.e., the arginine and lysine residues in 
exosite 2. Using those polymeric polydispersed structures as a guide, smaller molecules 
(dimers and trimers) were designed with similar scaffolds that were found to decrease the 
enzyme’s activity by different degrees, the first in this class of DTIs (Figure 8).50 
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Figure 6. Design concept for designing a heparin mimetic with an aromatic scaffold, with (A) 
heparin representative example of disaccharide unit and (B) LMWLs dimeric unit. 
  
P and Q = –OH, –OSO3– or OCH3 
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Figure 7. Chemo-enzymatic synthesis steps for the three LMWLs oligomers, CDSO3, FDSO3 
and SDSO3. Possible linkages are shown in shaded ovals. 
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1.6. Thrombin Structure 
Thrombin belongs to a wide class of enzymes activated by monovalent cations.51,52 
Several kinases and molecular chaperones require potassium for activation, while 
galactosidases and clotting proteases are activated by sodium.53 In the case of thrombin, sodium 
is not required for catalysis, but its presence greatly enhances the enzyme catalytic activity, so 
it is considered an allosteric effector.54-56 The first crystal structure solved for thrombin was in 
199257 with now almost 300 structures available in the PDB.58 Like all members of the 
chymotrypsin family, the enzyme has a characteristic fold, where two six-stranded β-barrels 
come together to form the catalytic triad H57, D102 and S195 at their boundary.59 The active 
site pocket has surrounding ridges of neighboring secondary structures, especially the 60-and 
γ‐loops, that determine the enzyme specificity for its substrates.60-62 It has two polypeptide 
chains, the A chain with 36 residues and the B chain with 259 residues, linked by a disulfide 
bridge between C1 and C122.  
In addition to its catalytic site, thrombin has three other separate domains, a sodium 
binding site and anion binding exosites 1 and 2 (Figure 9). Sodium is known to enhance 
thrombin’s catalytic activity, while exosites 1 and 2 control its interactions with natural ligands 
that modulate specificity. Exosite 1 is characterized by the presence of basic residues as well 
as hydrophobic patches covering its surface that causes electrostatic steering and 
complementarity for natural ligands like PARs. On the opposite side of the enzyme lies exosite 
2, formed by the C-terminal and its adjacent domain and has similar characteristic 
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electropositive exterior. This site is most famous for its interaction with polyanionic ligands 
like GAG chains of heparin.53  
 
Figure 9. Surface representation of thrombin with electrostatic potentials. More red 
emphasizes more basic surfaces. Important domains are labeled for clarity; image 
created from PDB file 1XMN using Sybyl 7.2.    
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Some ligands interact simultaneously with two sites; hirudin, for example, engages the 
active site as well as exosite 1.63 Several other natural ligands bind both exosites, such as 
fibrinogen, which mainly interacts with exosite 1, while the acidic part of its γ’ chain binds 
with high affinity to exosite 2.64 Thrombomodulin hydrophobic domain interacts with exosite 
1, while its terminal chondroitin sulfate sequence binds to exosite 2.65 Double binding with 
both exosites is also seen with some inhibitors like bothrojaracin.66 Lately, the GpIb receptor 
was postulated to bind to thrombin in a model that involves each exosite involved with a 
different GpIb molecule, suggesting a more complex binding events where both exosites 
interplay.67 
Lastly, the sodium binding site is a remote 16 – 20 Å away from the catalytic triad, yet 
a mere 5 Å from D189 of S1 site. The specificity of the enzyme for Na+ is high, almost 10-fold 
higher than other monovalent cations like Li+, K+ or Rb+.68 Binding causes thrombin activation 
and enhances its procoagulant functions. 
1.7. Thrombin Allosteric Network 
Binding at sodium binding site or at either one of the exosites has different, sometimes 
contradictory, effects on the enzyme’s active site. Allosteric signals after ligand binding are 
transmitted in the form of conformational changes at the active site that may or may not lead 
to changes in the enzyme specificity and/or catalytic efficiency in a ligand specific manner.62,65 
The traditional view of enzyme specificity is focused on the residues of the enzyme that 
constitute the active site. This was lately challenged in the case of thrombin and other 
coagulation factors in general. It is well recognized now that extended surfaces away from the 
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catalytic triad (i.e., exosites) play an important role in shaping the enzyme specificity as well 
as its efficiency.69,70  
1.7.1. Sodium and Active Site 
Thrombin catalytic efficiency is enhanced towards small chromogenic substrates as 
well as its natural macromolecular ligands after sodium binding. This led to the now well 
described designation of “fast” thrombin, when bound to sodium, which mainly acts on 
fibrinogen and PARs, while Na+ free “slow” thrombin with better catalysis geared towards 
protein C activation.60 The catalytic ability is not lost in the absence of sodium, so the 
monovalent cation is considered an allosteric effector rather than a cofactor.71 To assess the 
effect of sodium binding on the structure of the whole enzyme, the intrinsic fluorescence of 
thrombin mutants, where the nine tryptophans of thrombin were mutated one at a time to 
phenylalanine, was monitored upon binding of sodium. All mutants experienced a change in 
the fast phase of fluorescence increase that correlates with the kinetics of Na+ binding to 
thrombin. This indicated a global effect of sodium binding on the structure of the enzyme.72 
The thermodynamics of sodium binding was studied by monitoring the value of KA as 
a function of temperature. Binding of sodium is accompanied by a large enthalpy gain of -22 
kcal/mol arising from the formation of the metal six coordination interactions with 
thrombin,51,73 which is surprisingly compensated by a large entropy loss of -64 cal/mol.K. The 
entropy loss was explained by the ordering of water molecules inside a channel that links the  
sodium site with the specificity pocket and active site.73,74 This water network was postulated 
to transmit the allosteric signal from the sodium binding site to the active site by extending H-
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bonds from the sodium atom to the Oγ atom of S195 located 15 Å away in the active site and 
leading to generation of the so called “fast” thrombin form upon sodium binding (Figure 10).73 
The entropy change was accompanied by a large negative heat capacity change upon Na+ 
binding.68,75,76  
Figure 10. Difference between sodium bound thrombin (fast form in blue) and free thrombin 
(slow form in yellow) showing the main residues involved in sodium binding. 
Figure shows sodium as a yellow ball and illustrates the water network connecting 
sodium to the active site residues in fast (red balls) and slow (green balls) forms. 
The figure is adapted directly from reference 53.  
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The measured affinity of sodium was 110 mM (pH 8, I = 800 mM at 37 °C).The 
physiological sodium concentration is 140 mM and the prevalent thinking was that sodium is 
thus 60% in the fast – sodium bound – form and 40% in the slow free form.53 These figures 
have been lately challenged by measuring the affinity of sodium near physiological conditions, 
which provided a much higher affinity for thrombin (KD = 5 mM), and would render the 
enzyme almost saturated with sodium in blood.77 
1.7.2. Exosite 1 and Active Site 
Binding of thrombomodulin to exosite 1 alters the specificity of thrombin from 
fibrinogen cleavage to activation of protein C, which acts as a switch to shift thrombin from a 
procoagulant to an anticoagulant enzyme. Hirudin binds through hydrophobic interactions to 
the active site while its C-terminal dodecapeptide (residues 54-65), called hirugen, binds to 
exosite 1 (Figure 11).63 When hirugen alone binds, it causes alteration of thrombin catalytic 
efficiency (KCAT/KM) for small chromogenic substrates. Kinetic studies show that the catalytic 
efficiency increases or decreases by almost 2-fold according to the used substrate.65,78 On the 
other hand binding of active site inhibitors leads to increasing affinity of exosite 1 ligands, 
which proves the thermodynamic linkage between the two sites.79 Detailed studies were 
conducted on a self-inhibited thrombin mutant, where the entire 215-219 β‐strand is collapsed 
leading to blocked access to the active site. Binding of a fragment of PAR-1 receptor to exosite 
1 of thrombin led to a large conformational change that modified the strand and reestablished 
the access to the active site.80 A recent study using NMR proved that binding of sodium or 
exosite 1 ligands individually stabilize thrombin, but the fully active conformation is only 
attained when binding occurs at both, or when the active site is occupied.81 
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Figure 11. Thrombin complex with the acidic C-terminal of hirudin (hirugen). Electrostatic 
potential of thrombin surface is presented where more blue indicates more basic 
surface. Hirugen is depicted in stick representation with carbon in yellow, oxygen 
in red and nitrogen in blue. Figure adapted from reference 60. 
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1.7.3. Exosite 2 and Active Site  
Binding of heparin to exosite 2 of thrombin leads to its irreversible inactivation by 
antithrombin by the bridging mechanism. Testing with small chromogenic and fluorogenic 
peptide substrates proves that heparin does not have an effect on the catalytic efficiency of the 
enzyme.46,47,82 Our lab recently reported the first molecules that binds to thrombin exosite 2 
and directly causes thrombin inhibition. The molecules were designed based on heparin 
structure with the polysaccharide backbone replaced with an aromatic scaffold that bears the 
same combination of sulfate groups. Instead of inhibiting thrombin in the presence of AT using 
the bridging mechanism like heparin, these lignin based polymeric chains were able to inhibit 
thrombin independent of AT in an allosteric manner.48,49 This added another layer to the 
complexity of thrombin allostery, proving for the first time an energetic link exists between 
exosite 2 and the active site that could be tweaked to inhibit the enzyme if triggered by the 
suitable effector. These polymers were used as a template upon which smaller molecules were 
designed that were found to impart the same action of inhibiting the enzyme catalytic activity.50 
1.7.4. Exosite 1 and 2    
There are a large number of studies, often contradictory, debating the interconnection 
between thrombin exosites. Some studies report contrasting fluorescence signals of 
fluorescein-FPR-thrombin when hirudin binds to exosite 1 and the prothrombin F2 fragment 
binds to exosite 2. These results showed that binding at the two exosites is mutually exclusive 
as binding of one ligand led to displacement of the other.83 A study corroborated those early 
findings, showing that binding different exosite 2 ligands altered γA/γA fibrinogen peptide or 
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fibrinogen binding and prolonged clotting time. The study also included direct binding studies 
by surface plasmon resonance (SPR) in which ligands bound at one exosite decrease or abolish 
binding at the second.84 Controversially, another study reports the same peptides bind 
simultaneously without changing each other’s KD, implying that a ternary complex can be 
formed with both exosites occupied.85 
Thrombin is an attractive target in the coagulation cascade. The market has a myriad of 
anticoagulants that target this key serine protease, yet none of those agents is ideal. The 
complex structure of thrombin and the intricate allosteric network that regulates its functions 
is striking. It offers the possibility to design agents that act with new mechanisms to achieve 
the required inhibition and at the same time avoid the side effects of conventional therapy. The 
recently designed LMWLs offer a rare chance of modulating thrombin catalytic machinery via 
an allosteric mechanism that utilizes a direct energetic link between exosite 2 and thrombin 
active site. This link was not known to exist before, with literature mainly highlighting linkages 
that connect the active site, sodium binding site and exosite 1. This is mainly due to the fact 
that few molecules beside GAGs bind to exosite 2, and none leads to inhibition of thrombin. 
Rational design of smaller molecules based on the polymeric structures led to identification of 
a new series of compounds that act in the same allosteric manner to inhibit thrombin. Further 
studies were needed to identify the exact site of binding of these molecules and to dissect the 
nature of their interaction. These studies would be extremely useful in understanding this new 
model of inhibition and further design better agents acting by the same mechanism.  
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Chapter 2: Rationale 
    2.1. Background 
Coagulation enzymes are trypsin-like serine proteases with very similar structures. 
Designing a specific inhibitor is difficult, especially due to the high conservation of their active 
site architecture. Yet, specificity can be engineered using the subtle differences between them. 
An interesting aspect is that nature tends to be less meticulous in conserving allosteric sites in 
comparison to active sites, which offers a better chance of selectivity. With the high risk of 
bleeding associated with current therapies, allosteric modulators offer the chance of controlling 
the enzyme catalytic efficiency better than through total blockage with competitive inhibitors. 
Keeping a part of the enzyme physiological activity can be the key to preventing some of the 
current drugs side effects. Another advantage is the possibility of preventing toxicity by 
administering a silent allosteric molecule that competes with the allosteric inhibitor for the 
same binding site so as to act as antidote, if needed. As most of the marketed drugs are 
injectable, there is a need for designing novel inhibitors bearing scaffolds with drug-like 
properties, improved pharmacokinetics and water solubility that confers oral bioavailability. 
Of all the molecules available in the market, rivaroxaban seems to be the closest to what is 
considered an ideal anticoagulant.1  
     2.2. Heparins 
 Typically, it is difficult to rationally target an allosteric site of an enzyme, which implies 
that the discovery of allosteric inhibitors is mainly based on serendipity. Our lab has been 
developing heparin mimetics as thrombin inhibitors. Heparin is a polydisperse, highly sulfated 
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heterogeneous polymer that binds to exosite 2 of thrombin, which is an electropositive domain. 
This domain includes basic residues that bind to heparin’s sulfate groups, mainly Arg93, 
Arg101, Arg233, Lys236, and Lys240 (Figure 12).86  
 
Figure 12. Surface representation of thrombin exosite 2 with electrostatic potential, where the 
more basic the residue is, the bluer it is colored. Heparin derived hexasaccharide 
is co-crystallized and shown in stick representation (carbon in white, oxygen in red 
and sulfur in yellow). Sulfate groups are shown interacting with labeled key 
arginines and lysines. Figure directly adapted from reference 86.   
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In vitro, heparin binds to thrombin with a wide range of affinity, depending on the 
molecular weight of heparin chain used, the salt concentration of the experimental buffer, pH 
and the nature of thrombin used (free or inhibited). The interaction is electrostatic, which 
renders it highly sensitive to salt concentration. Using active thrombin, lower molecular weight 
heparin chains (Mr 7,900) bound with KD 6 – 10 μM, while longer chains (Mr 17,300) bound 
with KD 2 μM, at physiological conditions of 150 mM NaCl.28 Another experiment reproduced 
a similar value of 1 μM affinity for high molecular weight heparin (Mr 11,000), yet reported a 
huge increase in affinity (KD 5.8 nM) when NaCl was removed from the buffer.87 Similar 
figures were previously obtained in a third study conducted without NaCl that showed a KD of 
1.7 nM.88 The affinity of active site inhibited thrombin showed a different discrepancy, where 
in 100 mM NaCl the KD was measured to be 35 nM.89 This highlights the importance of the 
ionic strength of the buffer. 
Heparin and LMWH serve merely as molecular bridges that brings thrombin closer to 
its natural serpin inhibitor, antithrombin, accelerating the inhibition by almost 1,000 – 4,000 
fold.22 Many heparin mimetics have been designed, but their anticoagulant mechanism is 
similar to heparin, thus carrying heparin’s side effects.1 Based on heparin structure, our lab 
advanced low molecular weight lignins (LMWLs) as heparin mimetics. The design was based 
on the idea of replacing the polysaccharide backbone in heparin with a less problematic, more 
drug-like aromatic scaffold decorated by sulfate and carboxylate groups that would interact 
with the basic residues of exosite 2 on thrombin surface.  
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     2.3. Exosite 2 Allosteric Inhibitors  
Three polymeric molecules were synthesized: CDSO3, FDSO3 and SDSO3 from the 
corresponding 4-hydroxycinnamic acid monomers, caffeic acid, ferulic acid or sinapic acid.49 
Initial investigation showed that unlike heparin, which requires antithrombin for inhibition, the 
sulfated lignins were able to directly inhibit thrombin. Further work with CDSO3 confirmed 
that it inhibits thrombin allosterically through exosite 2.48 To develop smaller molecules based 
on the sulfated lignin scaffold, our laboratory designed a series of sulfated benzofuran dimers 
and trimers that also showed good thrombin inhibition capability.50 To better understand how 
LMWLs and the sulfated benzofurans interacted with thrombin at the molecular level, two of 
the sulfated lignins (CDSO3 and FDSO3) (Figure 7) and two sulfated benzofurans, a dimer 
(SBD) and a trimer (SBT) were selected for further studies (Figure 13).  
Figure 13. Structure of the benzofuran compounds selected for further studies, a dimeric 
compound SBD and trimeric one SBT.  
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There are many questions that need further exploration with these mechanistically novel 
molecules. Do they all bind at the same binding site? If they all bind at exosite 2, do they have 
the same orientation or binding mode? What are the types of forces involved in their 
interactions? The two polymers studied, CDSO3 and FDSO3, have similar polydispersity in 
scaffold, linkage and sulfation pattern. Physicochemical studies indicated that FDSO3 is more 
negatively charged, which allows it to form more ionic interactions with the thrombin surface.90 
The most notable difference was in the side chains. CDSO3 had a larger number of hydroxyl 
groups since the synthesis starts with the more polar caffeic acid compared to the more 
hydrophobic methoxy group in ferulic acid, which is the building unit of FDSO3. This promoted 
the idea that CDSO3 will probably have a better chance of hydrogen-bonding with exosite 2 
polar residues. Binding of both polymers was expected to follow the polyelectrolyte theory of 
binding like heparin, where interaction is highly dependent on the salt concentration of the 
medium.  
The small molecules were, on the other hand, an uncharted area; their design was based 
on the polymeric chains, but will they actually act as allosteric modulators? Will they bind to 
exosite 2 as well? These were the first synthetic small molecules that were designed to inhibit 
thrombin via an allosteric mechanism. The first step was to check if they bind in exosite 2 using 
a competitive enzyme inhibition assay. As the molecules contained one sulfate group each, they 
were expected to interact with one of the basic lysines or arginines in exosite 2. It was hard to 
predict whether extending the chain from two to three units would affect the binding and the 
mode of inhibition.  
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As the first thrombin inhibitors to bind at exosite 2, LMWLs offer an attractive chance 
to further investigate the allostery of thrombin. Is there a direct energetic link between exosite 
2, where the molecules bind, and the active site? There are no studies in the literature that 
discuss this link, simply because, other than these molecules, there are no reported molecules 
that inhibit thrombin through this exosite. As it is also known that sodium changes the 
conformation of the enzyme from the slow to the fast form, do the polymers decrease sodium 
affinity to the enzyme and thereby inactivate thrombin or is it a direct linkage between exosite 
2 and the active site? It was also interesting to see if the conformational change to the fast form 
is correlated with the binding affinity of the polymers, which would clarify the linkage between 
exosite 2 and sodium binding site.  
These studies will shed new light on the complex allosteric network of thrombin and 
the modulation of its catalytic functions as well as aid in further development of new molecules 
that act by the same new mechanism. In the following chapters I will present the detailed work 
done to analyze the site of binding of these novel molecules and identify the key residues 
involved in their interaction. A detailed study of the salt dependence of CDSO3 and FDSO3 
binding as well as their thermodynamics will be discussed. 
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Chapter 3: Identification of the Binding Site and Key Residues Required 
for Interaction of LMWLs on Thrombin 
    3.1. INTRODUCTION 
Allosteric regulation of coagulation enzymes, especially factors IIa, Xa, IXa, and XIa, 
is a fundamental property exploited by nature.1,91 The primary allosteric regulator of these 
coagulation enzymes is heparin, an animal-derived, phenomenally complex, linear 
polysaccharide. Polymeric heparin binds to those factors in a site remote from the active site 
of the enzymes and enhances their inhibition by AT.10 Although heparins have been used as 
anticoagulants for the past eight decades, they are beset with a number of adverse reactions 
including enhanced bleeding risk, immunological reaction, poor oral bioavailability, patient-
to-patient response variability, narrow therapeutic index, possibility of contamination and 
others.1,92,93 Yet, few macromolecular mimetics of heparin have been developed so far because 
of their massive structural complexity, difficulty of synthesis and lack of effective 
macromolecule design tools. 
To address some of these issues, we recently designed synthetic macromolecules, called 
sulfated LMWLs, as inhibitors of coagulation.48,49,94 Chemo-enzymatically synthesized 
sulfated LMWLs are sulfated oligomers of varying lengths and substitution patterns that 
attempt to mimic the structural diversity of heparins.49 However, they are completely unlike 
LMWH with respect to the nature of their backbone. In contrast to the highly anionic, 
carbohydrate scaffold of the heparins, sulfated LMWLs possess an aromatic scaffold decorated 
with fewer sulfate and carboxylate groups. The combination of a hydrophobic scaffold with 
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anionic groups generates physicochemical properties that induce novel protein recognition 
characteristics.90 In this respect, sulfated LMWLs are proving to be unlike any other class of 
anticoagulants investigated to-date, including the heparins, the coumarins, the hirudins, the 
peptidomimetics and the small molecule direct inhibitors.1,95 
Functionally, the three designed sulfated LMWLs – CDSO3, FDSO3 and SDSO3–
display a plasma and blood anticoagulation profile similar to that of LMWH.94 The focus of 
this work will be mainly on two of these polymers that are structurally related, CDSO3 and 
FDSO3. Physicochemical studies indicated that FDSO3 is more negatively charged, which 
allows it to form more ionic interactions with thrombin surface.90 The most obvious difference 
is in the side chains: CDSO3 has larger number of hydroxyl groups since the synthesis starts 
with the more polar caffeic acid compared to the more hydrophobic methoxy group in ferulic 
acid, which is the building unit of FDSO3 (Figure 14). Enzyme inhibition studies showed that 
these molecules potently inhibit thrombin, factor Xa and plasmin in an antithrombin–
independent manner.49,96 Mechanistic inhibition studies have shown that CDSO3 utilizes 
exosite 2 of thrombin to induce inhibition.48 This novel mechanism distinguishes those 
inhibitors from the heparins, which do not directly inhibit any coagulation enzyme. In fact, 
sulfated LMWLs appear to be the only molecules that allosterically induce inhibition of 
thrombin through an exclusive exosite 2 interaction. 
To elucidate the site of binding of sulfated LMWLs, we focused on FDSO3, a prototype 
molecule. We utilized Michaelis-Menten kinetics and competitive enzyme inhibition assays to 
identify its binding site. In these experiments a competitor known to bind to either exosite 1 or 
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2 of thrombin is added to the medium and the inhibition by FDSO3 was monitored. If the 
competitor binds to the same site as the studied molecule, increasing the competitor 
concentration would lead to a progressive decrease in FDSO3 inhibition. Three competitors 
were used, hirugen peptide analogue [5F]-Hir[54-65](SO3-) (HirP) for exosite 1 and 
unfractionated heparin (UFH) as well as an octasaccharide fragment derived from heparin (H8) 
for exosite 2. We also studied the inhibition properties of CDSO3 and FDSO3 against a panel 
of single, double and triple site-directed thrombin mutants, where all basic residues in exosite 
2 are mutated to Ala to abolish its charge. Sulfate and carboxylate groups of CDSO3 and FDSO3 
utilize the lysine and arginine basic amino acids lining thrombin exosite 2. We hypothesized 
that by modifying one or more of those residues to alanine, the key residues vital to binding 
can be identified.  
     3.2. EXPERIMENTAL  
   3.2.1. Proteins, LMWLs, Chemicals and Reagents.  
Sulfated dehydropolymers CDSO3 and FDSO3 (Figure 14) were synthesized in two 
steps from 4-hydroxycinnamic acid monomers, caffeic acid and ferulic acid, using chemo-
enzymatic synthesis.49 Human α-thrombin was purchased from Haematologic Technologies 
(Essex Junction, VT). Chromogenic substrates Spectrozyme TH (H-D-hexahydrotyrosol-Ala-
Arg-p-nitroanilide) and S2238 (H-D-Phe-Pip-Arg–p-nitroanilide) were purchased from 
American Diagnostica (Greenwich, CT) and ANASPEC (Fremont, CA), respectively. 
Unfractionated porcine heparin was purchased from Sigma (St. Louis, MO). Heparin 
octasaccharide H8 was purchased from V-Labs (Covington, LA). Hirugen analog, Tyr63-
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sulfated hirudin54-65 labeled with 5-(carboxy) fluorescein ([5F]-Hir[54-65](SO3-)) (HirP), was 
a gift from the Bock laboratories and its preparation was described earlier.97 All other chemicals 
were analytical reagent grade from either Sigma Chemicals (St. Louis, MO) or Fisher 
(Pittsburgh, PA) and used as such.  
3.2.2. Recombinant Thrombin Mutants  
Recombinant wild-type and mutant thrombins were prepared in the Rezaie laboratory 
at St. Louis University School of Medicine, as described earlier.98,99 Briefly, Arg93Ala, 
Arg97Ala, Arg101Ala, Arg126Ala, Arg165Ala, Lys169Ala, Arg173Ala, Arg175Ala, 
Arg233Ala, Lys235Ala, Lys236Ala, Lys240Ala, Arg93,97Ala, Arg93,101Ala, Arg97,101Ala 
or Arg93,97,101Ala thrombin were prepared in prothrombin-1 form by PCR mutagenesis and 
expression in baby hamster kidney cells (BHK) using the pNUT-PL2 expression/purification 
vector system. The mutants were purified to homogeneity by immunoaffinity chromatography 
using the Ca2+-dependent monoclonal antibody, HPC4, and activated to thrombin. The active-
site concentrations of thrombin mutants were determined by an amidolytic activity assay and 
stoichiometric titrations with antithrombin.98,99 These concentrations were within 90–100% of 
those expected on the basis of their absorbance at 280 nm. Stock solutions of these mutants 
were prepared in 20 mM sodium phosphate buffer, pH 7.4, containing 100 mM NaCl and 2.5 
mM CaCl2. 
 
 
 
 
37 
 
3.2.3. Michaelis-Menten Kinetics of Substrate Hydrolysis by Thrombin in the 
Presence of FDSO3.  
Several concentrations of Spectrozyme TH (0.5–80 μM) were hydrolyzed by 2 nM 
wild-type thrombin in presence of fixed concentration of FDSO3 (0.48–2.38 μM). The initial 
rate of substrate hydrolysis was monitored from the linear increase in A405 in 20 mM Tris-HCl 
buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2 and 0.1 % PEG 8000 in PEG 20,000-
coated acrylic cuvettes at 25 °C. The data obtained was fitted by the standard Michaelis-Menten 
equation to calculate the apparent KM and VMAX. 
3.2.4. Competitive Binding Studies with a Hirugen analog HirP, H8 or Porcine 
Unfractionated Heparin (UFH).  
The inhibition effect of FDSO3 on wild-type thrombin was studied in the presence of 
either HirP, H8 or UFH in a manner similar to that described above for direct thrombin 
inhibition. Briefly, a solution of FDSO3 (0.24 – 24 µM) and thrombin (4 nM) was mixed at 25 
°C with either HirP (0 – 103 nM), H8 (0 – 25 μM) or UFH (0 – 25 μM) in 20 mM Tris-HCl 
buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2 and 0.1 % PEG 8000 in PEG 20,000-
coated acrylic cuvettes. Following mixing, hydrolysis of Spectrozyme TH (20 µM) was 
monitored at 405 nm. The dose-dependence of the fractional residual thrombin activity at each 
concentration of the competitor was fitted using equation 1 to obtain the apparent concentration 
of FDSO3 required to inhibit thrombin activity by 50% (IC50,app).  
ࢅ ൌ ࢅࡻ ൅ ࢅࡹିࢅࡻ૚ା૚૙൫ܔܗ܏ሾࡸࡹࢃࡸሿ૙ష࢒࢕ࢍࡵ࡯૞૙൯ൈࡴࡿ           (equation 1) 
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In this equation, YM and YO are the maximum and minimum values of the fractional 
residual thrombin activity; HS is Hill slope and IC50 is the concentration of the inhibitor that 
results in 50% inhibition of enzyme activity. Sigmaplot 8.0 (SPSS, Inc., Chicago, IL) was used 
to perform nonlinear curve fitting in which YM, YO, HS and IC50 were allowed to float. 
3.2.5. Quantitative Measurement of Wild-type and Mutant Thrombin Inhibition 
Potential of CDSO3 and FDSO3.  
The two polymers inhibition of recombinant wild-type and mutant thrombins was 
studied in a manner identical to that described earlier for human plasma thrombin. The buffer 
used for these experiments was 20 mM Tris–HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 
mM CaCl2 and 0.1% PEG 8000 in PEG 20,000-coated acrylic cuvettes. Either Spectrozyme 
TH or S2238 was used as substrate and the residual thrombin activity was quantified by 
measuring the initial rate of hydrolysis from the linear increase in absorbance at 405 nm as a 
function of time under conditions where less than 10% substrate is consumed. Briefly, a 
solution of 10 μl CDSO3 or FDSO3 at concentrations ranging from 0.1 to 8.6 mM was diluted 
with 963 μl of buffer and 7 μl of 0.23–1.07 μM thrombin and mixed well. This was followed 
by addition of 20 μl of either S2238 (0.8 mM) or Spectrozyme Th (2 mM) and the initial rate 
was rapidly measured. Logistic equation 1 was used to fit the dose dependence of residual 
thrombin activity to obtain YM, YO, HS and IC50 of inhibition. 
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     3.3. RESULTS 
3.3.1. Allosteric Inhibition of Thrombin is a Common Property of Sulfated 
LMWLs.  
Earlier work with CDSO3 inhibition of thrombin has shown that the direct inhibitor 
reduces the forward rate constant of hydrolysis of a peptide substrate, i.e., Spectrozyme TH, 
without affecting its Michaelis constant.48 Structurally, FDSO3 and CDSO3 are oligomers of 
either 3-methoxy or 3-hydroxy analogs of 4-hydroxy cinnamic acid, respectively (Figure 14). 
They may be expected to have identical complex structures, however, oligomerization is known 
to proceed with some selectivity, which induces subtle compositional differences.100 We 
reasoned that for identifying the site of binding on thrombin, a prototypic sulfated LMWL is 
needed.  
Earlier we have shown that CDSO3 does not bind in the active site or exosite 1 of 
thrombin.48 To assess whether FDSO3 exhibits a similar phenomenon, we studied the 
Michaelis-Menten kinetics of Spectrozyme TH hydrolysis by wild-type thrombin at pH 7.4 and 
25 °C in the presence of FDSO3. Michaelis-Menten constants were derived by non-linear 
regression analysis of the initial rate versus Spectrozyme TH concentration profiles (Figure 
15). Table 1 lists the calculated apparent VMAX and KM values. As the concentration of FDSO3 
increased, the KM was found to essentially remain constant, while the VMAX decreased nearly 
2.8-fold. This indicates that the presence of FDSO3 does not affect the affinity of binding of 
Spectrozyme TH in the active site of thrombin, but induces some changes that significantly 
reduce the rate of conversion of the Michaelis complex into products. This implies a non-
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competitive type of inhibition induced by FDSO3. Thus, the results support the conclusion that 
allosteric inhibition of thrombin is a common property of sulfated LMWLs. 
3.3.2. FDSO3 Does Not Bind in Exosite 1 of Thrombin.  
To test whether FDSO3 binds in the exosite 1, we measured the effect of a hirugen 
analog, [5F]-Hir[54-65](SO3-) (HirP), on the IC50 of FDSO3 inhibition of thrombin. HirP binds 
exclusively in exosite 1 of thrombin with an affinity of 4 nM.85,97 Thus, the apparent IC50 of 
FDSO3 inhibition of thrombin in the presence of HirP was measured in a dose-response assay 
as described earlier. The presence of HirP did not significantly affect the thrombin inhibition 
profiles as shown in figure 16. Fitting the dose-response equation 1 to the data indicated that 
the apparent IC50 remained essentially invariant as the HirP concentration increased from 8.8 
nM to 103 nM (Table 2). A quantitative comparison of the observed versus the predicted KD 
(IC50 in our case) assuming ideal competition can be obtained by applying the Dixon-Webb 
calculation:  
ܭ஽,௣௥௘ௗ௜௖௧௘ௗ. ൌ 	ܭ஽ ൈ ൬1 ൅ ሾ஼௢௠௣௘௧௜௧௢௥ሿ○௄಴೚೘೛೐೟೔೟೚ೝ ൰   (equation 2) 
Kcompetitor refers to the equilibrium dissociation constant of the competitor (HirP) – 
thrombin complex, which was measured independently under otherwise identical conditions. 
A visual representation helps to clarify how the IC50 is almost unchanging compared to the 
predicted values obtained from the Dixon–Webb calculation with increasing competitor 
concentration if the competition was ideal (Figure 17). Likewise, the maximal inhibition 
induced by FDSO3 in the presence of HirP, i.e., ΔY = YM – Y0, also did not alter significantly 
(~60%, see Table 2) with the concentration of the competitor. This suggests that the exosite 1 
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ligand induces no change in the efficacy of FDSO3 inhibition of thrombin, just as it induces no 
change in the potency of inhibition. Thus, in a manner similar to CDSO3, FDSO3 also does not 
appear to bind in the anion-binding exosite 1 of thrombin. 
3.3.3. Competition with UFH is a Common Property of Sulfated LMWLs.  
Previous studies have indicated that CDSO3 does not interact with the hirudin-binding 
site (exosite 1) of thrombin, but binds in or near the heparin-binding site, referred to as exosite 
2.48 A wide range of affinities have been reported in literature for polymeric heparin binding to 
coagulation enzymes. This is primarily because of the heterogeneity present in the heparin 
preparations. For example, the affinity of FXa, FIIa and FIXa for heparin has been measured 
in the range of 0.006–10 μM using several reaction conditions,27,28,86-89,101,102 while that of FXIa 
has been found to be ~10 nM.12,103 To probe if FDSO3 displays similar characteristics to 
CDSO3, the apparent IC50 was measured in the presence of porcine unfractionated heparin. 
Figure 18A shows the dose-response profiles of FDSO3 inhibition of thrombin in the presence 
of 4.2 to 25 μM porcine heparin. A distinct shift in the profiles is observed as the concentration 
of the competitor increases suggesting competition between the two ligands for thrombin 
binding. The apparent IC50 increases by 8-fold in the presence of 25 μM heparin (Table 2). This 
suggests that FDSO3 and full-length heparin compete for binding to exosite 2 of thrombin in 
an almost ideal manner based on the Dixon-Webb calculations (Figure 19A). Yet, the efficacy 
of inhibition increases from 56% to 76% as the concentration of UFH changes from 0 to 25 
μM, which appears to indicate that the two ligands may be interacting in a partially co-operative 
manner. 
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To test whether FDSO3 competes with smaller heparin chains, competitive inhibition 
studies were performed in the presence of heparin derived octasaccharide H8. As the 
concentration of H8 increased from 1 to 25 μM, the apparent IC50 did not change significantly 
(Figure 18B, Table 2). This indicates that FDSO3 and H8 do not compete with each other, 
although both are exosite 2 ligands. The results become more apparent by comparing the 
obtained values with the Dixon-Webb predicted ones assuming ideal competition (Figure 19B). 
Interestingly, the presence of H8 increased the maximal inhibition from ~50% to 70% at the 
highest concentration studied, further supporting the conclusion that FDSO3 and smaller 
heparin chains may simultaneously bind in exosite 2 and possibly interact in a cooperative way 
(Table 2). Taken together, these results show that FDSO3 binds in exosite 2 but at a site distinct 
from the site of H8. Combining these results with other studies,48,96,104 the experiments show 
that sulfated LMWLs compete with UFH for recognizing multiple coagulation enzymes. Thus, 
engaging an exosite 2-like domain in the targeted coagulation proteases appears to be a generic 
property of these novel inhibitors. 
3.3.4. Site-Directed Mutagenesis of Thrombin Exosite 2 Residues Indicates Key 
Role of Arg93, Arg97 and Arg101 in Recognition of FDSO3.  
Exosite 2 of thrombin is a considerably large ellipsoidal region spanning an area of 
approximately 20×30 Å2. It consists of several basic residues including Arg173, Arg175, 
Arg101, Arg93, Arg97, Arg126, Lys235, Lys240, Lys236, Arg165, and Lys169. We reasoned 
that the negatively charged sulfate and carboxylate groups of LMWLs are likely to interact 
with one or more of these basic residues. Thus, to identify the residues that play important role 
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in FDSO3 recognition, we studied inhibition of a library of thrombin mutants containing single, 
double and triple replacement of Arg/Lys to Ala. As a group, the library included all the basic 
residues present in exosite 2 of thrombin. The preparation and characterization of these 
thrombins have been described earlier98,99 and each thrombin mutant was screened for direct 
inhibition by FDSO3 in a manner similar to that used for wild-type thrombin (Table 3). To 
ascertain the generality of inhibition properties in key mutants, two chromogenic substrates – 
Spectrozyme TH and S2238 – were used in these studies. 
The dose – response profiles of most of the twelve single mutants studied in this work 
were essentially identical to the recombinant wild type enzyme. The IC50 measured for alanine 
replacements for Arg93, Lys235, Arg165, Arg175, Arg173, Arg233, Lys240, and Arg236 
ranged from 0.79 μM to 1.12 μM, while that measured for the wild-type enzymes was 0.98 
μM. Two thrombin mutants – Lys169Ala and Arg97Ala – displayed slightly stronger inhibition 
potency (2.3–2.6-fold) than the wild-type, while Lys126Ala and Arg101Ala displayed a 1.4–
1.6-fold defect (Table 3). The maximal inhibition efficacy of FDSO3 across these thrombin 
mutants ranged from 40 – 79% in comparison to 47% observed for the recombinant wild-type. 
These results suggest that single-point mutations appear to not induce major defect in FDSO3 
– thrombin interaction.  
To test the possibility that multiple point charges may be involved in binding, we 
evaluated double and triple mutants of 93, 97 and 101 residues. Mutation at those specific 
residues was reported to alter the binding of some exosite 2 ligands including heparin.98 We 
hypothesized, based on the competition of FDSO3 with heparin, that similar alteration of 
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FDSO3 binding could occur. Replacement of two arginines at these positions – either 93,97 or 
97,101 or 93,101 – right shifted the dose-response profile in comparison to the wild-type 
enzyme (Figure 20). The measured IC50 for the 97,101-double mutant was 1.6 μM, while those 
for 93,97- and 93,101-double mutants were 1.8 and 2.7 μM, which represent 1.6-, 1.8-, and 
2.7-fold increases in IC50 over corresponding controls (Table 3). 
Replacement of all three arginines with alanines introduced a major defect in thrombin 
inhibition by FDSO3. The IC50 measured using Spectrozyme TH hydrolysis was 56 μM 
suggesting a dramatic defect of 57-fold, while that measured using S2238 hydrolysis indicated 
a similar defect of 49-fold (Figure 20, Table 3). These results suggest that the three arginines 
at 93, 97, and 101 positions are collectively critical for interacting with FDSO3. Further, the 
massive increase in the order of defect upon mutation of all three arginines suggests that the 
three positive charges appear to work simultaneously (or interchangeably) in recognizing 
FDSO3. Similar results were obtained when studying the interaction between thrombin and the 
fibrinogen γ’ chain, where none of the acidic residues in the peptide were found to be critical 
for the binding, yet an ensemble of three residue mutations led to abolishing the affinity. The 
authors’ conclusion was that the peptide recognized thrombin through electrostatic 
complementarity with the three residues imposing the specificity of the interaction.105 
The efficacy of inhibition for the triple mutant (~98%, Table 3) is also considerably 
enhanced in comparison to all other thrombins studied in this work. The basis for the significant 
increase is not clear, although it is important to recognize that FDSO3 inhibition of wild-type 
thrombin appears to be primarily a kCAT effect, which probably arises from conformational 
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changes induced in the active site. This induced conformational change can be different for 
each thrombin molecule resulting in variable efficacies of FDSO3 inhibition. 
3.3.5. Specific Residues of Thrombin Are Involved in Recognition of CDSO3.  
Earlier studies supported the exosite 2-like site as the prime site of CDSO3 recognition. 
To identify the key residues of exosite 2 that are important for CDSO3 binding, we studied 
inhibition of the same library of thrombin mutants. Direct inhibition of these mutants by 
CDSO3 was studied in a manner similar to that used for wild-type thrombin.48 Alanine 
replacement at Arg97, Arg101, Lys235, Lys236, or Lys240 positions did not affect the CDSO3 
inhibition potency (0.9–1.5-fold effect), while substitutions at the 165, 169, 173 and 233 
positions introduced a 2.2–3.7-fold decrease in inhibition potency (Table 4). The measured 
IC50s for Arg93Ala and Arg175Ala thrombin mutants were 313 and 275 nM, which were 7–8-
fold greater than that of the recombinant wild-type thrombin (39 nM) (Table 4, Figure 21). The 
maximal inhibition efficacy of CDSO3 across these thrombin mutants ranged from 47% to 82% 
in comparison to 58% observed for the recombinant wild-type form. These efficacies are 
generally similar to that noted earlier for human plasma thrombin and human plasma plasmin 
(~80%).48  
To assess the effect of multiple replacements on CDSO3 inhibition potency, double and 
triple replacement at the 93, 97, and 101 positions were studied. Replacing arginines at both 93 
and 97 positions with alanines shifted the dose–response profile significantly to the right in 
comparison to both the wild-type enzyme as well as either single-site mutants (Table 4, Figure 
22). The measured IC50 for the 93,97-double mutant was 679 nM, which indicated an increase 
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of 17-fold and 2-fold over wild-type and Arg93Ala enzymes, respectively. Introducing alanines 
for arginines at 93, 97, and 101 positions led to an increase in IC50 of 36-fold from the wild-
type form (Figure 22). The efficacy of inhibition for the double and triple mutants was again 
comparable to other thrombins studied in this work (~80%, Table 4). 
    3.4. DISCUSSION 
Sulfated LMWLs were initially designed to mimic the global structural complexity and 
anticoagulant property of heparins. The novel molecules do mimic the anticoagulant activity, 
but are proving to be strikingly different from the polysaccharide counterparts in nearly all 
other respects. Thus, whereas heparins do not directly inhibit thrombin, fXa and other clotting 
enzymes, sulfated LMWLs were found to potently inhibit thrombin and factor Xa48 and 
moderately inhibit plasmin.96 Nearly all other enzymes of the coagulation cascade as well as 
trypsin and chymotrypsin are not affected by sulfated LMWLs.104 This selectivity is interesting 
because it represents an excellent opportunity for designing macromolecular anticoagulants, a 
task that is known to be more challenging than designing traditional small molecule 
anticoagulants. For molecules that can be readily prepared in high yields using simple chemical 
and enzymatic reactions,49 the exceptional anti-coagulant activity was striking. Recently, 
physicochemical studies have highlighted another interesting characteristic of these novel 
molecules. Sulfated LMWLs appear to possess unusually high solubility in organic solvents 
despite the presence of a number of anionic groups.90 These interesting structural, mechanistic, 
biological and physicochemical properties imply that understanding the molecular aspects of 
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the interaction of sulfated LMWLs with target proteins may lead to the design of novel 
anticoagulants that are radically different from all the molecules being pursued to date.  
A priori, exosite 2 of thrombin is known to bind highly anionic molecules such as 
heparin1,86,99,106 and chondroitin sulfate,65 while exosite 1 is known to bind anions that are 
significantly hydrophobic, e.g., hirudin.107,108 Studies with peptides have suggested that highly 
anionic peptides prefer exosite 2 in comparison to exosite 1, which prefers less anionic and 
more hydrophobic peptides.62 Thus, sulfated LMWLs, which are much less anion-dense and 
significantly more hydrophobic than LMWH, were expected to recognize exosite 1. It was 
surprising to observe that CDSO3 prefers interacting with exosite 2 of thrombin.48 Thus to 
further understand the basis for thrombin inhibition by sulfated LMWLs, we studied FDSO3 
which is also a prototypic inhibitor in this class and the only sulfated LMWL found to date to 
potently inhibit factor IXa.104  
This work demonstrates that FDSO3 does not bind in exosite 1 of thrombin and prefers 
to interact with exosite 2, while chromogenic substrate hydrolysis studies indicate that FDSO3 
disrupts the catalytic apparatus in a manner similar to CDSO3. Thus, FDSO3 is also an allosteric 
inhibitor of thrombin function. A key aspect for the development of this explanation was 
competition observed with polymeric heparin. UFH is known to interact with Arg93 and 
Arg101 as well as other residues of exosite 2.86,109 Most probably, polymeric heparin sterically 
blocks exosite 2 resulting in competition with sulfated LMWLs. Alternatively, polyanionic 
UFH may electrostatically protect the exosite too. 
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The library of exosite 2 residue mutants studied in this work has led to a more refined 
model of CDSO3 and FDSO3 interaction site on thrombin. Of the twelve electropositive 
residues constituting exosite 2, three residues – Arg93, Arg97 and Arg101 – were found to 
collectively play a critical role in FDSO3 inhibition mechanism. All three residues belong to 
the 99-loop of thrombin and are known to interact with full-length heparin,86,109 thus explaining 
its competitive effect. A particularly challenging question to address is the nearly complete lack 
of inhibition defect when the three critical residues are mutated individually. FDSO3 is a 
complex preparation consisting of numerous sequences that are structurally distinct.90 The 
presence of several types of inter-residue linkages (β-5, β-O-4, β-β and others) in FDSO3 
preparation probably overcomes a defect created by a single point mutation through 
compensating sequence(s) that utilize another binding mode. Such alternative sequences and 
interaction geometries would imply that a functionally defective thrombin inhibition may only 
be possible if all or most critical residues are mutated.  
CDSO3 has different recognition elements. Arg93 and Arg175 showed 7 – 8-fold defect 
in CDSO3 inhibition. Four other residues which form an arch-like structure surrounding the 
two key residues (Figure 23) appear to be less important with 2 – 3-fold impaired inhibition. 
The model suggests a well-defined binding pocket where the CDSO3 chains appear to bind. 
The differences obtained between CDSO3 and FDSO3 from the mutant library data highlights 
the fact that despite the common structural features, the two polymeric inhibitors have their 
differences.  
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Designed sulfated LMWLs are structurally unique anticoagulants. The molecules are strikingly 
different from any other class of anticoagulant investigated to-date. The generic allosteric 
regulation mechanism coupled with identification of the binding site is expected to facilitate 
the design of molecules based on their scaffold. Another advantage with regard to exosite 2-
mediated allosteric regulation of coagulation enzymes is an excellent possibility of an antidote 
strategy with non-inhibitory sulfated carbohydrates. For example, small oligosaccharides that 
bind in exosite 2 without inducing direct inhibition, such as sucrose octasulfate, may serve as 
effective antidotes of sulfated LMWLs-based anticoagulants, which would impart considerable 
safety to it. 
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Table 1. Michaelis-Menten kinetics of spectrozyme TH hydrolysis by wild-type 
thrombin in the presence of FDSO3.a 
[FDSO3]O 
(μM) 
Spectrozyme TH 
KM  VMAX 
 (μM) (mAU/min) 
0 4.8  1.2b 39.0  2.5 
0.48 4.1  0.8 27.5  1.4 
0.96 2.6  0.6 15.9  0.9 
2.38 3.3  1.1 14.1  1.2 
aKM and VMAX were measured as described in ‘Experimental’. 
bError represents 1 S.E. 
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Table 2. Inhibition of wild-type thrombin by FDSO3 in the presence of hirugen analog 
HirP, porcine heparin, or heparin octasaccharide H8.a 
 
[Competitor] IC50 (μM) Y0 YM ΔY HS 
Hirugen Analog 
8.6 nM 1.3  0.2b 38  3 106  6 68  9 1.4  0.3 
25.8 nM 1.7  0.1 37  1 104  2 67  3 1.8  0.2 
51.6 nM 1.3  0.1 36  2 104  3 68  6 2.1  0.3 
103 nM 1.5  0.1 39  2 101  2 62  4 2.1  0.3 
Porcine Heparin 
0 μM 0.7  0.2 44  3 109  11 65  11 1.8  0.6 
4.2 μM 1.9  0.4 43  3 101  6 58  8 1.7  0.6 
12.8 μM 4.4  1.3 26  1 112  6 86  8 0.9  0.3 
25 μM 5.7  0.6 24  3 103  3 79  12 1.2  0.2 
Heparin Octasaccharide H8 
1 μM 1.2  0.1 53  2 98  3 45  3 2.3  0.5 
3 μM 1.6  0.1 46  1 101  2 55  2 1.7  0.2 
10 μM 1.8  1.0 31  3 115  6 84  13 0.7  0.3 
25 μM 1.2  0.1 50  1 99  3 49  3 2.2  0.4 
 
a Inhibition studies were performed in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 
mM CaCl2 and 0.1 % PEG 8000 in PEG 20,000-coated polystyrene cuvette. Spectrozyme TH was used 
as substrates and the residual enzyme activity in the presence of FDSO3 was assessed by measuring the 
initial rate of substrate hydrolysis at 405 nm. Logistic equation 1 was used to fit the dose dependence of 
the residual enzyme activity to obtain log IC50, Y0, YM and HS values. See Methods for details. 
b Error represents 1 ±S.E. 
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Table 3. Inhibition of recombinant wild-type and mutant thrombins by FDSO3.a 
 
Thrombin IC50 (M) Y0 YM Yb HS 
Using Spectrozyme TH as Substrate   
WT 0.98  0.09c 54  2 101  2 47  2 2.4  0.4 
R93A 0.79  0.09 36  2 93  3 57  5 1.6  0.3 
R97A 0.42  0.06 42  1 106  4 63  4 1.2  0.2 
R101A 1.58  0.15 28  1 101  1 73  3 0.6  1.3 
R126A 1.39  0.06 49  1 102  1 54  2 2.0  0.2 
R165A 0.82  0.06 40  1 101  1 61  3 1.6  0.2 
K169A 0.38  0.04 41  1 98  2 57  3 1.6  0.2 
R173A 0.99  0.16 60  1 100  2 40  2 1.2  0.2 
R175A 0.83  0.15 47  3 103  6 56  6 2.4  0.8 
R233A 1.00  0.05 37  2 102  2 66  4 2.3  0.3 
K235A 0.81  0.07 33  2 101  2 68  5 1.5  0.2 
K240A 1.10  0.08 42  2 104  3 61  4 2.3  0.4 
R236A 1.12  0.26 23  6 102  4 79  25 0.7  0.1 
R93A,R97A 1.79  0.10 37  1 101  1 74  2 1.2  0.1 
R101A,R93A 2.73  0.59 49  3 100  2 51  3 1.7  0.5 
R101A,R97A 1.63  0.19 28  2 103  2 75  8 0.9  0.1 
R101A,R93A,R97A 56.0  2.70d 0 101  1d ~98d 0.9  0.1d 
Using S2238 as Substrate   
WT 0.85  0.04 43  1 99  1 56  2 2.6  0.3 
R93A,R97A 1.38  0.16 38  2 98  2 60  4 1.5  0.2 
R101A,R93A 2.51  0.30 48  2 100  2 52  4 1.8  0.4 
R101A,R97A 1.21  0.13 35  2 104  2 69  4 1.0  0.1 
R101A,R93A,R97A 41.7  4.80d 0 99  1d 98  1d 1.1  0.1d 
 
a Inhibition studies were performed in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 
mM CaCl2 and 0.1 % PEG 8000 in PEG 20,000-coated polystyrene cuvettes. Either Spectrozyme TH 
or S2238 were used as substrates and the residual enzyme activity in the presence of FDSO3 was 
assessed by measuring the initial rate of substrate hydrolysis at 405 nm. Logistic equation 1 was used 
to fit the dose dependence of the residual enzyme activity to obtain log IC50, Y0, YM and HS values. See 
Methods for details. 
b difference between YM and Y0. 
c Error represents 1 ± S.E. 
d values derived from fitting the inhibition profile using Y0 = 0.  
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Table 4. Inhibition of recombinant wild-type and mutant thrombins by CDSO3.a  
 
Thrombin IC50 (nM) Y0 YM Yb S 
WT 38.92  0.37c 47  1 105  3 58  3 1.2  0.2 
R93A 313.18  3.13 21  2 103  2 82  9 1.3  0.2 
R97A 37.13  0.53 49  2 102  3 53  4 0.8  0.3 
R101A 36.45  0.64 33  3 101  4 68  9 0.5  0.2 
R165A 144.58  3.93 27  5 95  4 68  16 0.5  0.3 
K169A 85.35  1.72 33  3 98  3 65  8 0.5  0.1 
R173A 115.35  2.13 52  2 99  2 47  3 0.5  0.2 
R175A 275.17  2.93 34  2 100  2 66  5 0.8  0.1 
R233A 86.14  2.07 30  5 99  4 69  14 0.5  0.2 
K235A 43.90  0.79 32  3 101  4 69  9 0.7  0.2 
K240A 57.03  0.82 27  2 103  4 76  9 0.6  0.1 
R236A 57.77  0.35 20  1 102  1 82  5 1.0  0.1 
R93,R97A 679.36  17.55 25  5 96  5 71  18 0.3  0.3 
R93,97,101A 1415.14  20.61 18  3 98  2 80  11 0.6  0.1 
 
a Inhibition studies were performed in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 
mM CaCl2 and 0.1 % PEG 8000 in PEG 20,000-coated acrylic cuvettes. S2238 was used as substrate 
and the residual enzyme activity in the presence of CDSO3 was assessed by measuring the initial rate of 
substrate hydrolysis at 405 nm. Logistic equation 1 was used to fit the dose dependence of the residual 
enzyme activity to obtain log IC50, Y0, and YM values. See Methods for details. 
b difference between YM and Y0. 
c Error represents 1 ± S.E. 
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Figure Legends 
Figure 14. Representative structure of the two polymeric chains studied, CDSO3 and 
FDSO3 . The chains shown have β-O-4, β-5, β-β and 5–5 inter-residue linkages 
(shown shaded). X and Y are substituents at α‐ and β- positions and may be –
H, –OH, or –OSO3Na and –H or COONa, respectively. R may be either –OH 
or –OSO3Na in CDSO3 or –OCH3 in FDSO3. Variations in these substituents, 
inter-residue linkages and configuration at α- or β- positions generate a large 
number of sequences.  
Figure 15. Michaelis-Menten kinetics of Spectrozyme TH hydrolysis by thrombin in the 
presence of FDSO3. The initial rate of hydrolysis at various substrate 
concentrations was measured in pH 7.4 buffer as described in ‘Experimental’. 
Solid lines represent non-linear regressional fits to the data using the Michaelis-
Menten equation. 
Figure 16. Competitive effect of HirP on the inhibition of wild-type thrombin by FDSO3. 
Residual thrombin activity was measured through Spectrozyme TH hydrolysis 
in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2 
and 0.1 % polyethylene glycol (PEG) 8000 at 25 OC in the presence of 0 to 103 
nM HirP. Solid lines represent fits using the logistic equation 1 to obtain the 
apparent IC50, as described in ‘Experimental’. 
Figure 17. Comparison of the observed (black bars) versus the predicted (white bars) IC50 
values of FDSO3 inhibition in presence of HirP. The calculations were based on 
the Dixon-Webb equation 2. 
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Figure 18.  Competitive effect of UFH (A) and octasaccharide H8 (B) on the inhibition of 
wild-type thrombin by FDSO3. Residual thrombin activity was measured 
through Spectrozyme TH hydrolysis in 20 mM Tris-HCl buffer, pH 7.4, 
containing 100 mM NaCl, 2.5 mM CaCl2 and 0.1 % polyethylene glycol (PEG) 
8000 at 25 OC in the presence of 0 to 25 M UFH (A) and 0 to 25 M H8 (B). 
Solid lines represent fits using the logistic equation 1 to obtain the apparent IC50, 
as described in ‘Experimental’. 
Figure 19. Comparison of the observed (black bars) versus the predicted (white bars) IC50 
values of FDSO3 inhibition in presence of A) UFH and B) H8. The calculations 
were based on the Dixon-Webb equation 2. 
Figure 20. Dose-response profile of direct inhibition of multi-point thrombin mutants by 
FDSO3 in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM 
CaCl2 and 0.1 % polyethylene glycol (PEG) 8000 at 25 OC. Mutants include 
Arg93,101Ala, Arg93,97Ala, and Arg93,97,101Ala. Inhibition of the thrombin 
mutants by FDSO3 was followed as described in ‘Experimental’. Solid lines 
represent sigmoidal dose-response fits of equation 1 to obtain values of IC50, 
HS, Y0 and YM. 
Figure 21. Dose-response profile of direct inhibition of thrombin wild-type and mutants by 
CDSO3 in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM 
CaCl2 and 0.1 % polyethylene glycol (PEG) 8000 at 25 OC. Single point mutants 
include Arg93Ala and Arg175Ala. Inhibition of the thrombin mutants by 
CDSO3 was followed as described in ‘Experimental’. Solid  lines represent 
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sigmoidal dose-response fits of equation 1 to obtain values of IC50, Y0, YM and 
HS. 
Figure 22. Effect of single site (A) and multi-site (B) replacement of electropositive 
residues of exosite 2 of thrombin on the direct inhibition potency of CDSO3. 
The ratio of IC50 values of the mutant to that of recombinant wild-type is shown. 
‘Dbl mut’ refers to Arg93,97Ala thrombin, likewise ‘Trp mut’ refers to 
Arg93,97,101Ala thrombin. Error bars shown are ± 1 S.E.  
Figure 23. The overall structure of thrombin indicating the putative binding site of CDSO3 
(PDB ID – 1TB6). The electropositive residues studied in this work are 
highlighted. The carbon atoms of these residues are color-coded based on the 
magnitude of the decrease in inhibition by CDSO3 upon mutation to alanine 
(red: > 7-fold, green: 2 – 3-fold and white: < 2-fold). The protein backbone is 
shown as a ribbon and the 60-loop (blue), 99-loop (yellow), 170-loop (cyan) 
and C-terminal region (magenta) are highlighted. 
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Chapter 4: Identification of the Mechanism of Inhibition, the Binding Site and 
Key Residues Required for Interaction of Small Molecule Inhibitors with 
Thrombin 
     4.1. INTRODUCTION 
The coagulation cascade is a rich assembly of homologous serine proteases. Each 
enzymatic factor of the cascade recognizes a P-1 arginine residue in its target, which sets up 
possible cross-over reactivity with enzymes of other systems too. Nature avoids this promiscuity, 
especially of macromolecular substrates, through clever engineering of the environment around 
the enzyme active sites, known by extended surfaces. For example, thrombin contains the 60-loop, 
the 149-insertion loop and the bulky Trp215 residue to restrict access to its active site.53,64,110 Such 
stringent steric and/or electronic natural ‘gating’ assists in the design of selective small molecule, 
active site inhibitors. Yet, the process remains challenging and is threatened by cross-reactivity 
with closely related enzymes, e.g., factor Xa, or with enzymes that exhibit too broad substrate 
specificity, e.g., trypsin. In addition to steric or electronic ‘gating’, an alternative strategy that 
nature exploits for engineering high selectivity is the use of exosites.  
Discovering allosteric modulators of protein function is challenging and yet highly sought 
after considering that this form of regulation is suggested to offer finer control necessary for 
therapeutic success, which is difficult to achieve with competitive, active site inhibitors because 
of the drive to achieve very high potency. At a fundamental level, small molecules may be designed 
so that the allosteric conformational change can exhibit tailored balance between pro- and anti- 
coagulant activities that diminishes the current therapeutics side effects. Another advantage of 
allosteric regulation is the possibility of greater specificity of recognition arising from greater 
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differences in exosite geometries compared to active sites. In effect, allosteric regulation promises 
to afford exquisite control over both specificity of recognition and efficacy of inhibition. Despite 
this expectation, allosteric modulators of cardiovascular enzymes, other than heparin and 
heparinoids, have not been vigorously pursued. 
A classic example of natural allosteric regulation is thrombin cleavage of fibrinogen. In 
this process, the substrate binds to exosite 1, which then enables its efficient cleavage.53,64,106,110 
Likewise, binding of full-length heparin in exosite 2 enables a much faster inhibition of thrombin 
by the antithrombin – heparin complex.10,22 In addition to this exquisite dual recognition, exosites 
afford a fine opportunity for allosteric modulation of catalytic machinery. Both exosites 1 and 2 of 
thrombin as well as exosites of many other coagulation enzymes are coupled with the active site. 
Although the intricate mechanism of this coupling is not fully understood in all cases, it is known 
that it may involve alteration of structure of the catalytic triad and/or of neighboring residues. For 
example, sodium binding is known to allosterically alter the conformation of the catalytic triad, 
shifting thrombin from the slow to the fast form,111 while heparin binding in exosite 2 is known to 
change the electrostatics around the active site with minimal change in catalytic activity.82,112,113 
But there are very few examples such as hirugen114 and bothrojaracin,115 where these allosteric 
sites were utilized to inhibit the catalytic activity of thrombin. Those and other allosteric ligands 
such as heparin, chondroitin sulfate, and haemadin are either long peptides or highly anionic GAG 
molecules.66 There has been no report of inhibiting coagulation activity of thrombin allosterically 
by small, synthetic molecules. 
Many heparin mimetics were designed, either polypeptides or polysaccharide fragments 
derived from heparin, to act clinically as anticoagulants. Heparins are associated with numerous 
side effects such as narrow therapeutic window, excessive bleeding, and dose response variability 
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among patients.116 Other alternatives of smaller oligosaccharides suffer from high production costs 
and potential toxicity.117 Thus, the requirement for overcoming the safety problem and regular 
monitoring requirement drives the research for development of new orally bioavailable, potent and 
safe antithrombotic agent. To develop such regulators of thrombin, we started with the design of 
heparin mimetics that are sulfated low molecular weight lignins (LMWLs), which were found to 
potently inhibit thrombin, factor Xa and plasmin.48,49,94,96 The oligomeric molecules targeted 
exosite 2 of thrombin exclusively and were the first molecules in the class of exclusive exosite 2-
based allosteric modulators of thrombin.48 Sulfated LMWLs prevented human blood from clotting 
in ex-vivo assays with potency comparable to low molecular weight heparins (LMWHs) and thus 
represented molecules of considerable interest.94 Yet, the oligomeric nature of these molecules did 
not bode well for clinical potential.  
To address this issue, we designed sulfated benzofuran monomers based on the scaffold of 
sulfated LMWLs (Figure 24A), which were found to allosterically inhibit thrombin and factor Xa, 
albeit with poor potency (IC50 in mM range).118 Subsequent advances in the design led to sulfated 
benzofuran dimers that exhibited a range of inhibition potencies (μM to mM) and efficacies (20 – 
60%).50 A second generation library of trimers containing three linked benzofuran units was 
synthesized to improve the potency and solubility of the compounds. In this work, we present 
detailed biochemical studies on the interaction of thrombin with two selected representatives of 
those molecules, a sulfated benzofuran dimer (SBD) and trimer (SBT), with a goal of identifying 
the site of binding for further rational structure-based drug design (Figure 24).  
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    4.2. EXPERIMENTAL  
4.2.1. Thrombin, Peptides, Chemicals and Reagents.  
Human α-thrombin was from Haematologic Technologies (Essex Junction, VT). Stock 
solutions of thrombin were prepared in 20 mM sodium phosphate buffer, pH 7.4, containing 100 
mM NaCl. Chromogenic substrates Spectrozyme TH (H-D-hexahydrotyrosol-Ala-Arg-p-
nitroanilide) was purchased from American Diagnostica (Greenwich, CT) and S2238 (H-D-Phe-
Pip-Arg–p-nitroanilide) was purchased from ANASPEC (Fremont, CA). Unfractionated porcine 
heparin (UFH) was purchased from Sigma (St. Louis, MO). Heparin octasaccharide (H8) was 
purchased from V-Labs (Covington, LA). Tyr63-sulfated hirudin-(54-65) (HirP) was a generous 
gift from Dr. Paul Bock and its preparation has been described earlier.97 A peptide corresponding 
to the 20 amino acids at the carboxyl terminal of γ’-fibrinogen chain (VRPEHPAETE-Y(PO3)-
DSL-Y(PO3)-PEDDL) was obtained from Dr. David Farrell.31 All other chemicals were analytical 
reagent grade from either Sigma Chemicals (St. Louis, MO) or Fisher (Pittsburgh, PA) and used 
as such.  
4.2.2. Recombinant Thrombin Mutants.  
Recombinant wild-type and mutant thrombins were prepared in the Rezaie laboratory, as 
described earlier.98,99 Briefly, Arg93Ala, Arg97Ala, Arg101Ala, Arg126Ala, Arg165Ala, 
Lys169Ala, Arg173Ala, Arg175Ala, Arg233Ala, Lys235Ala, Lys236Ala, Lys240Ala, 
Arg93,97Ala, Arg93,101Ala, Arg97,101Ala and Arg93,97,101Ala thrombins were prepared in 
prothrombin-1 form by PCR mutagenesis and expression in baby hamster kidney cells (BHK) 
using the pNUT-PL2 expression/purification vector system. The mutants were purified to 
homogeneity by immunoaffinity chromatography using the Ca2+-dependent monoclonal antibody, 
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HPC4, and activated to thrombin. The active-site concentrations of thrombin mutants were 
determined by an amidolytic acivity assay and stoichiometric titrations with antithrombin.98,99 
These concentrations were within 90-100% of those expected on the basis of their absorbance at 
280 nm. 
4.2.3. Inhibition of Thrombin by Chromogenic Substrate Hydrolysis Assay. 
Thrombin activity in the presence of inhibitors was studied using chromogenic substrate 
hydrolysis assay in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2 and 
0.1 % polyethylene glycol (PEG) 8000 in PEG 20,000-coated acrylic cuvettes. Spectrozyme TH 
was used as substrate and the residual thrombin activity was quantified by measuring the initial 
rate of hydrolysis from the linear increase in absorbance at 405 nm as a function of time as reported 
earlier. Briefly, a solution of 10 μL of the inhibitors to form final concentrations ranging from 4.5 
– 900 μM for SBD and 0.045 – 22.5 µM for SBT was diluted with 970 μL of buffer and 5 μL of 1 
μM thrombin (5 nM) and incubated for 10 min for SBD and overnight for SBT. This was followed 
by addition of 15 μL of 2 mM Spectrozyme TH (30 μM) and the initial rate was rapidly measured. 
Logistic equation 1 was used to fit the dose dependence of residual thrombin activity to obtain 
IC50.  
ࢅ ൌ ࢅࡻ ൅ ࢅࡹିࢅࡻ૚ା૚૙൫ܔܗ܏ሾࡸࡹࢃࡸሿ૙ష࢒࢕ࢍࡵ࡯૞૙൯ൈࡴࡿ       (equation 1) 
In this equation Y is the ratio of residual thrombin activity in the presence of the inhibitor 
to that in its absence; YM and Y0 are the maximum and minimum possible values of the residual 
percentage of thrombin activity, respectively; HS is Hill slope and IC50 is the concentration of 
inhibitors that results in 50% inhibition of enzyme activity. Sigmaplot 8.0 (SPSS, Inc. Chicago, 
 
 
72 
 
IL) was used to perform non-linear curve fitting in which YM, YO, HS and IC50 were allowed to 
float. 
4.2.4. Michaelis-Menten Kinetics of Substrate Hydrolysis by Thrombin in Presence of 
SBD or SBT.  
The initial rate of Spectrozyme TH hydrolysis by 5 – 10 nM thrombin was monitored from 
the linear increase in absorbance at 405 nm corresponding to less than 10% consumption of the 
substrate. The initial rate was measured as a function of various concentrations of the substrate (2 
– 600 µM) in the presence of fixed concentration of either SBD (0 – 30 μM) or SBT (0 – 9.9 µM). 
SBD was incubated with thrombin for 10 min while SBT was incubated either over night at 25 °C 
or for two hours at 37 °C. The data was fitted by the standard Michaelis-Menten equation to 
determine KM and VMAX.  
4.2.5. Competitive Studies with Exosite 1 and Exosite 2 ligands.  
The inhibition effect of SBD or SBT on wild-type thrombin was studied in the presence of 
exosite 1 ligand, hirugen, a twelve residue hirudin peptide containing fluorescein at its N-terminus, 
[5F]-Hir[54-65](SO3-). Inhibition experiments were also performed in the presence of exosite 2 
ligands, heparin octasaccharide H8, porcine heparin (UFH) and γ’-fibrinogen peptide (FibP) in a 
manner similar to that described above for direct thrombin inhibition. Briefly, a solution of 10 μL 
of SBD (0–1000 µM) or SBT (0.045 – 22.5 µM) and 10 μL thrombin (4 – 10 nM) was mixed at 
25 °C with 10 μL of the competitor at appropriate stock concentration in 20 mM Tris-HCl buffer, 
pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2 and 0.1 % PEG 8000. The solution was incubated 
for 10 min for SBD and overnight for SBT at 25 °C followed by addition of Spectrozyme TH while 
monitoring the increase in absorbance at 405 nm. The dose-dependence of the fractional residual 
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thrombin activity at each concentration of the competitor was fitted using equation 1 to obtain 
IC50, YM, YO and HS. 
4.2.6. Inhibition of Recombinant Thrombin Mutants.  
Direct inhibition of thrombin mutants by SBD or SBT was measured through a 
chromogenic substrate hydrolysis assay, as reported with wild-type plasma thrombin. The buffer 
used in these experiments was 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM 
CaCl2, and 0.1% polyethylene glycol (PEG) 8000. Either Spectrozyme TH or S2238 was used as 
substrate for SBD and SBT respectively. SBD (2 to 30 μL) at concentrations ranging from 0.25 to 
12.5 mM or SBT (0.5 – 150 μL) at 90 µM were diluted with appropriate volume of assay buffer in 
PEG 20,000-coated acrylic cuvettes at 25 °C. To this solution, 5 μL of thrombin solution was added 
to give approximately 1.5 – 7.5 nM final concentration. Following addition of thrombin, 20 μL of 
either 1 mM Spectrozyme TH or 2 mM S2238 was added after the required incubation. The 
residual thrombin activity was then measured from the initial rate of increase in absorbance at 405 
nm. Relative residual thrombin activity at each concentration of the inhibitor was calculated from 
the ratio of thrombin activity in the presence and absence of inhibitor. Logistic equation 1 was 
used to fit the dose-dependence of residual proteinase activity to obtain IC50, YM, YO and HS. 
     4.3. RESULTS 
4.3.1. SBD and SBT Are Allosteric Modulators of Thrombin.  
To understand the site of interaction of the inhibitors on thrombin, Michaelis-Menten 
constants were derived by non-linear regression analysis of the initial rate versus Spectrozyme TH 
concentration profiles in the presence and absence of the SBD and SBT (Figures 25 and 26, 
respectively). As the concentration of SBD increased, the VMAX decreased, while KM stayed 
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essentially unchanged, which indicates allosteric non-competitive inhibition of thrombin (Table 
5). SBT on the other hand caused a decrease in VMAX accompanied by a decrease in KM as well in 
both conditions studied (Table 6). This apparent increase in the enzyme’s affinity for substrate is 
considered the hallmark of uncompetitive, allosteric mechanism. Collectively the data indicate that 
both molecules act allosterically, yet the introduction of a third benzofuran unit in SBT caused it 
to work with a different inhibition mechanism.  
4.3.2. SBD and SBT Do Not Bind in Thrombin Exosite 1.  
Considering that anion-binding exosites 1 and 2 of thrombin recognize charged ligands, 
SBD and SBT were hypothesized to induce inhibition through one of these sites. Sulfated tyrosine-
containing hirudin, a 65 amino acid long polypeptide that binds in exosite 1 as well as active site, 
is known to be the most potent thrombin inhibitor.114 On the other hand, exosite 2 prefers highly 
sulfated oligosaccharides,62,86 molecules that are significantly different in nature from the small 
molecules studied in this work. This suggested that SBD and SBT may prefer to interact with 
exosite 1 of thrombin. To test the binding in exosite 1, the inhibition potency of both molecules 
was measured in the presence of a hirudin-based peptide [5F]-Hir[54-65](SO3-), abbreviated as 
HirP, a molecule known to exclusively engage exosite 1 of thrombin. HirP binds with a dissociation 
constant of 4 nM as measured independently under similar conditions. Its presence was expected 
to significantly reduce the potency of the studied inhibitor, if the two molecules competed for the 
same binding site.  
The IC50 was measured by quantifying thrombin’s hydrolysis of Spectrozyme TH in the 
presence of fixed concentration of HirP at pH 7.4 and 25 °C, as described earlier.48 A standard 
sigmoidal dose-response profile was observed for the inhibition of thrombin for both molecules at 
all concentrations of HirP (Figures 27, 28), which could be fitted by the logistic equation 1 to 
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obtain the potency (IC50) and efficacy (ΔY = YM – Y0) of inhibition. Varying the concentration of 
HirP from 0 – 30 nM resulted in no apparent change in IC50 for both molecules (Tables 7,8). This 
suggests that HirP and neither SBD nor SBT do not compete with each other for binding in anion-
binding exosite 1 of thrombin. 
A more quantitative test of competitive binding is the Dixon-Webb relationship (equation 
2), which predicts the effect of competition on a measured equilibrium parameter (KD or IC50).  
ܫܥହ଴,௣௥௘ௗ௜௖௧௘ௗ. ൌ 	 ܫܥହ଴ ൈ ൬1 ൅ ሾ஼௢௠௣௘௧௜௧௢௥ሿ○௄಴೚೘೛೐೟೔೟೚ೝ ൰         (equation 2) 
In this equation, Kcompetitor is the dissociation constant of thrombin–HirP complex. Figures 27 and 
28 show a comparison of the observed and predicted IC50 for both molecules at each studied HirP 
concentration, which clearly points to absence of competition. 
4.3.3. SBD Competes Partially with Full-length Heparin and Does Not Compete with 
a Heparin Derived Octasaccharide.  
Highly sulfated polysaccharide chains including heparin octasaccharide H8, low-molecular 
weight heparin, full-length unfractionated heparin (UFH), γ’  fibrinogen peptide (FibP) and 
chondroitin sulfate utilize the anion-binding exosite 2 to bind to thrombin.53,62,110 The major 
difference in how these polysaccharide ligands recognize thrombin is their span of interaction 
domain. Whereas H8 recognizes primarily Arg233, Lys235, Lys236 and Lys240, the full-length 
polymer recognizes a wider area that includes Arg93, Arg101, and Arg165 residues. None of these 
ligands affects the proteolytic activity of thrombin, which implies that inhibition assays could be 
used for exosite 2 competitive studies. To assess whether SBD interacts with exosite 2, we first 
studied competition with UFH. The sigmoidal dose-response profiles displayed a slight shift to the 
right with increasing concentration of UFH from 0 – 48 μM suggesting a noticeable competitive 
 
 
76 
 
phenomenon (Figure 29). The IC50 of SBD inhibition of thrombin at pH 7.4 and 25 °C was 
calculated to increase from 8.8 μM in the absence of UFH to 36.1 μM in the presence of 48 μM 
UFH (Table 7). This represents a progressive decrease in potency up to 4.1-fold at a UFH 
concentration ~5-times higher than the KD of thrombin – heparin complex.86 Such a decrease in 
potency is suggestive of inefficient competition, or more appropriately partial competition, as seen 
from applying the Dixon-Webb relationship (equation 2, Figure 30). This most probably indicates 
a partial overlap between the binding sites of SBD and UFH on thrombin exosite 2.   
Figure 29 shows the dose-response curves of SBD inhibiting thrombin in the presence of 
H8 at pH 7.4 and 25 °C. As the concentration of H8 was increased from 0 to 10 μM, the IC50 of 
thrombin inhibition increased from 2.7 to 3.7 μM (Table 7). This change in potency was almost 
negligible when compared to the predicted IC50 from the Dixon-Webb relationship (equation 2, 
Figure 30). Also, no noticeable change in the efficacy of inhibition was observed in the presence 
of H8. Thus, H8 does not compete with SBD for binding to thrombin, suggesting that it does not 
recognize Arg233, Lys235, Lys236, or Lys240 known to interact with H8 in exosite 2. This is not 
too unexpected considering the widely different structural features of the two molecules. H8 is a 
highly anionic polysaccharide, while SBD is a fairly hydrophobic small molecule with one 
negative charge.  
4.3.4. SBD Competes with γ’-Fibrinogen Peptide for Binding to Thrombin.  
The absence of competition for binding to thrombin with H8 eliminated the octasaccharide 
binding pocket as site of interaction for SBD. By the same token, partial competition observed 
with UFH suggested recognition of one or more electropositive residues of exosite 2. Yet, exosite 
2 of thrombin is a fairly extensive domain with a large number of basic residues, which makes it 
difficult to find the exact site and mode for the inhibitor interaction. To further reduce the number 
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of possibilities, competition with γ’-fibrinogen peptide (FibP) was studied. FibP is known to bind 
in exosite 2 by interacting with residues that bind to H8 (Arg233, Lys235, Lys236 and Lys240),36 
while also interacting with additional residues as demonstrated by NMR studies.119 In these 
studies, the C-terminal residues of FibP interact with Arg93, Arg97, Arg173 and Arg175 of exosite 
2. This makes FibP an excellent probe for studying interaction with this group of arginines that lie 
beyond the H8 binding site. Figure 31A shows the dose-response profiles of SBD inhibition of 
plasma thrombin in the presence of 0 to 6.5 μM FibP. A distinct shift in the inhibition profiles was 
observed as the concentration of FibP increased suggesting strong competition between the two 
ligands for thrombin binding. The apparent IC50 increased from 7.97 μM in the absence to 118 μM 
in the presence of 6.5 μM FibP (Table 7). Simultaneously, the efficacy of inhibition increased from 
~40% to 55%, which suggests that the two ligands may be interacting in a partially co-operative 
manner. 
The predicted IC50 for SBD inhibition of thrombin in the presence of different 
concentrations of FibP was calculated using the Dixon-Webb relationship (equation 2). Figure 31B 
shows a comparison of the observed and predicted IC50. Each of the measured values are higher 
than those predicted for FibP competition, which suggests a strong competitive effect. The reason 
for the more-than-predicted competitive effect of FibP is not easy to decipher; however, a small 
change in the affinity of FibP for thrombin under the experimental conditions is likely to 
significantly alter the predicted IC50. Overall, competition with FibP indicates that SBD binds in 
exosite 2 in a region away from the H8 binding residues and most probably with one or more of 
Arg93, Arg97, Arg173 and Arg175. 
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4.3.5. SBT Binds in Exosite 2 of Thrombin.  
The apparent IC50 was measured in the presence of the same three exosite 2 binding ligands 
used with SBD: UFH, H8 and FibP. Figure 32A shows the dose-response profiles of SBT inhibition 
of thrombin in the presence of 4.2 to 42.6 μM UFH as competitor. A distinct shift in the profiles is 
observed as the concentration of UFH increases suggesting ideal competition between the two 
ligands for thrombin binding as predicted by the Dixon-Webb relationship (equation 2, Figure 
32B). The apparent IC50 increases from 0.68 μM in the absence of heparin to 6.10 μM in the 
presence of 42.6 μM heparin (Table 8). This indicates that SBT and full-length heparin compete 
for binding to exosite 2 of thrombin. 
Further studies were done to narrow the site of interaction of SBT by testing if it competes 
with smaller heparin chains or FibP. As the concentration of H8 increased from 1 μM to 20 μM, 
the apparent IC50 did not change significantly (Figure 33A, Table 8). This indicates that SBT and 
H8 do not share the same binding area on thrombin, although both are exosite 2 ligands.  To 
confirm this observation, the apparent IC50 was also measured in the presence of FibP. The peptide 
is known to interact with thrombin overlapping with H8 binding site, but extending beyond it to 
reach the boundary of exosite 2. Figure 33B shows the dose-response profiles of SBT inhibition 
of thrombin in the presence of 0 to 6.5 μM FibP. Again, no shift in the profiles is observed as the 
concentration of the competitor increases suggesting no competition between the two ligands 
(Table 8). Using the Dixon-Webb relationship for both H8 and FibP confirmed the absence of 
competition for both competitors (Figure 34). Taken together, these results show that SBT binds 
in exosite 2 in a manner similar to full length heparin chains, but at a site distinct from H8 or FibP 
binding site. 
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4.3.6. Sulfated Benzofuran SBD Interacts with a Single Arginine of Exosite 2.   
To identify the basic residues that might play an important role in the dimer recognition, 
we studied the inhibition of five thrombin mutants containing single and triple replacement of 
Arg/Lys to Ala. The preparation of these mutants has been described earlier98,99 and each thrombin 
mutant was screened for direct inhibition by SBD in a manner similar to that used for recombinant 
wild-type thrombin. The rest of the mutant library was excluded from screening based on the 
absence of competition with H8. The dose – response profiles of three of the four single point 
mutants studied in this work were essentially identical to the recombinant wild type enzyme 
(Figure 35). The IC50 measured for alanine replacements for Arg175, Lys169, and Lys235 ranged 
from 5.9 μM to 9.0 μM, while that measured for the wild-type enzyme was 5.5 μM (Table 9). The 
triple point mutant Arg93,97,101Ala had a comparable IC50 of 5.0 μM suggesting none of the three 
amino acids contribute to SBD binding. This was quite different from our results with 
macromolecular sulfated LMWLs, which primarily relied on Arg93 and Arg175 for mediating their 
inhibitory role. Although the above mentioned basic residues do not contribute to SBD recognition, 
each site-directed thrombin mutant was inhibited more than the wild-type enzyme. For example, 
the efficacy of SBD inhibition (i.e., ΔY) increased to ~70% for the triple mutant in comparison to 
~30% for wild-type enzyme (Table 9). 
One particular thrombin mutant, Arg173Ala, was dramatically different. It displayed a 22-
fold increase in IC50 compared to the wild type enzyme. The efficacy of inhibition for this thrombin 
mutant was ~55% (Figure 35). This suggested that Arg173 was essential for thrombin binding and 
inhibition by SBD and related sulfated benzofuran derivatives. It is striking that a single residue, 
of the 12 electropositive residues present in exosite 2 of thrombin, was identified to be critical for 
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interaction. It indicates a high level of specificity of recognition, which suggests a strong 
possibility for development of allosteric thrombin inhibitors based on that scaffold. 
4.3.7. Trimer SBT Interacts with Specific Arginines in Exosite 2.  
To highlight the basic residues that play a significant role in binding, we studied the 
inhibition of 12 thrombin mutants containing single replacement of all Arg/Lys in exosite 2 to Ala. 
Each thrombin mutant was screened for direct inhibition by SBT using a more sensitive substrate, 
S2238. The activity dropped using this substrate by 2.5-fold to 0.261 μM for wild type thrombin 
versus Spectrozyme TH. The dose – response profiles of ten of the 12 single point mutants were 
essentially identical to the recombinant wild type enzyme (Figure 36). The IC50 measured ranged 
from 0.212 μM to 0.308 μM (Table 10). For one single mutant (Arg93Ala), the activity increased 
by 2-fold with the IC50 dropping to 0.169 μM, probably indicating a relief of a steric clash that 
decreased the inhibition potency in the wild type enzyme. This area of thrombin contains two 
closely spaced arginines, Arg93 and Arg101, suggesting they might be involved in a more complex 
manner in the interaction. Only one single mutant, Arg233Ala, showed a 3-fold drop in potency, 
which is more than any of the double mutants, indicating that Arg 233 is a key residue involved in 
the binding Most probably the residue forms a salt bridge with the sulfate group in SBT.  
This is in accordance with our previous results with the polymeric LMWLs that found Arg 
233 to be important for activity, lowering the potency by almost 2.5-fold, albeit with less 
importance than two other basic residues for the polymer binding, Arg 93 and Arg 175. These 
finding indicate that the trimeric units of benzofuran are able to bind in a similar fashion to at least 
some of the active polymeric species. Although the activity of SBT is still almost 10-fold less than 
the polymer, it offers the advantages of one defined, simple and homogenous structure that could 
be easily modified to improve potency, selectivity and pharmacokinetic parameters.  The binding 
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site is remarkably different from SBD, which bound mainly to Arg 173 at the edges of exosite 2 
and in proximity to the active site. Adding one more unit to form the trimer shifted the binding 
more towards the center of exosite 2. The polymers (FDSO3 and CDSO3) as well as the small 
molecules (SBD and SBT) share the same binding site with unfractionated heparin polymers, but 
unlike heparin they are able to directly inhibit thrombin in an antithrombin independent manner. 
This makes them a better heparin mimetic than the currently available options as they offer a more 
controlled safety profile, more selectivity and more specificity of interaction. 
Surprisingly, while Arg93Ala showed a 2-fold increase in potency, the double mutant 
Arg93,101Ala showed 2.5-fold drop in inhibition (Figure 36). This could be attributed to the 
proximity between Arg 233 on one end and the two basic residues Arg93 and Arg101 on the other 
end. The sulfate group linked to Arg 233 could form additional hydrogen bond interactions with 
either of these two basic residues. The triple mutant Arg93,97,101Ala had also 5-fold increase in 
IC50 highlighting again the importance of this constellation of basic residues in anchoring the 
position of the sulfate group. The same results were obtained with one of the polymeric chains 
studied (FDSO3), which again points to the resemblance in binding between these two inhibitors.  
     4.4. DISCUSSION 
Similar to heparin, the polymeric LMWLs are a complex mixture of different structures 
arising from different inter-residue linkages and degrees of sulfation. It is well known that the β-5 
linkage is the most abundant linkage present in the natural lignins.49,90 Based on this assumption 
and synthetic feasibility, the benzofuran scaffold was chosen due to its scaffold similarity to the β-
5 linkage (Figure 24). A series of molecules with dimeric and trimeric units of benzofuran based 
scaffold were recently synthesized in our lab. No small, drug-like molecules have been designed 
as yet that function as allosteric modulators of thrombin. SBD and SBT, which were designed as 
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mimetics of heparin, are the first small hydrophobic molecules that allosterically reduce thrombin’s 
catalytic activity.118,50 Discovering allosteric modulators is challenging because identifying 
exosites that are energetically coupled to the active site in an agonistic or antagonistic manner is 
not routinely possible. More importantly, even if such an exosite was known, designing molecules 
that fit the site ‘snugly’ and are able to cause a conformational change is challenging, because the 
classical, allosteric induced-fit mechanism would require good recognition of both the native and 
conformationally altered enzyme states. 
The advantage with thrombin is that it is a highly pliable enzyme. The presence of multiple 
exosites in thrombin enhances the likelihood of discovering small molecule allosteric regulators. 
However, such probabilistic advantage does not imply automatic translation into drug-like 
molecule design, and thrombin is no exception. The scenario with other coagulation enzymes, such 
as factors Xa, IXa and XIa, is similar. Yet, allosteric regulation of these enzymes offers phenomenal 
opportunity to induce tailored conformational change so as to maintain a delicate balance between 
bleeding and clotting tendencies. With this goal in mind, we designed sulfated LMWLs from which 
we designed the small molecule dimers and trimers, including SBD and SBT, respectively.48-
50,94,96,118 
This work suggests that SBD and SBT utilize two different sub-sites in exosite 2 to 
allosterically inhibit thrombin. Although designed as mimetics of heparin, SBD does not engage 
the traditional exosite 2 residues, including Arg101, Arg126, Lys235, Lys236 and Lys240.53,62,86,110 
The dimer recognizes Arg173, a heparin-binding residue, yet binding seems to occur in a region 
different from that predicted for sulfated CDSO3, which appears to bind in a linear segment present 
in exosite 2 on either side of residues Arg93 and Arg175 or FDSO3, which collectively utilizes 
Arg93, Arg97 and Arg101 for binding. On the other hand, when the same scaffold is extended by 
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one more benzofuran unit, SBT binds in a different way, more closely related to the polymeric 
chains. Despite the fact that two of the double mutants had 2 – 2.5-fold defects in binding, the 
single mutant Arg233 displayed a 3-fold defect (Figure 36), which makes this residue,  known to 
be important for heparin binding, stand out as the major residue for trimer interaction. The triple 
mutant impaired inhibition proved the importance of the constellation of residues Arg93, Arg97 
and Arg101, in regulating the binding of SBT in a manner seen before in FDSO3 polymeric chains. 
The mechanism of inhibition changes as well from the non-competitive in the case of SBD 
to uncompetitive in the case of SBT, which further highlights the difficulty of predicting the 
behavior of these allosteric modulators using traditional structure-activity relationships. The IC50 
of SBD for thrombin inhibition at pH 7.4 and 25 °C is approximately 6 μM, which implies a 
reasonably high affinity interaction. A 1000-fold improvement in potency was found on moving 
from monomer to dimer SBD, which led us to design the trimer SBT, which had almost another 
10-fold improvement in potency over the dimer.   
SBD reduces thrombin’s catalytic activity approximately 50% (Table 7) in comparison to 
known inhibitors that target the active site and exosite 1.119-122 This implies that it does not 
completely inhibit the pro-coagulant signal. Whereas this could be traditionally considered as a 
defect of design, considering the problems of over-anticoagulation induced by thrombin inhibitors, 
the less than perfect reduction in catalytic activity of thrombin may serve to create the fine balance 
between procoagulant and anticoagulant signals. More importantly, detailed inhibition profiles 
reveal that SBT exhibits almost 90% efficacy, while for other related dimers and trimers it is 
between 10 and 20%.50 The variability in the efficacy of thrombin inhibition suggests that the 
equilibrium between the native and conformationally altered state is ‘tunable’ and optimally 
designed molecule(s) may be effective in treating varying levels of pro-coagulant tendencies. 
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The discovery of the new allosteric binding pockets and the benzofuran scaffold that is able 
to bind tightly and regulate thrombin activity raises many questions before a clinically viable 
candidate can be realized. For example, it is well established that presence of FibP does not affect 
thrombin-cleavage of fibrinogen,123 but reduces the cleavage of other thrombin substrates, such as 
factor V, factor VIII, platelet glycoprotein 1 and PAR-1. Our earlier work has shown that SBD 
inhibits clotting of human plasma, which implies that presence of this molecule reduces the rate 
of fibrinogen cleavage by thrombin.50 But if these molecules also reduce platelet glycoprotein 1 
and PAR-1 cleavage, SBD may function as a dual anti-platelet and anti-coagulant agent. This does 
not necessarily imply a distinct advantage because of the possibility of introducing bleeding risk. 
Future studies will clarify these involved aspects. 
Overall, this work presents two new binding pockets, one near Arg173 and one inside next to 
Arg233, that are energetically coupled to the active site, and two small, synthetic, hydrophobic 
molecules that recognize these sites with reasonably high affinity. The allosteric mechanism of 
thrombin inhibition could prevent the hemorrhagic complications and avoid narrow dosing 
regimens that are characteristic of thrombin active site inhibitors.124 Much remains to be learned 
about these novel binding sites, but structure-based drug design is expected to greatly enhance the 
‘druggability’ of this site. The successful design of allosteric inhibitors of thrombin opens the path 
for designing the allosteric inhibitors for other upstream proteases of coagulation cascade. The 
recognition of heparin binding site by these aromatic inhibitors may extend the inhibition activity 
for other proteases that are known to bind heparin. Exploring the other structural features of 
lignins, it may be possible to find scaffolds inhibiting other proteases in a highly specific manner. 
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Table 5. Michaelis-Menten kinetics of Spectrozyme Th hydrolysis by thrombin in presence 
of SBD.a 
 
[SBD]  KM VMAX 
(M) (M) (mAU/min) 
0 18.9  4.4b 100.4  9.3 
3 15.5  5.1 106.8  13.0 
10.5 15.9  3.8 72.7  11.6 
30 15.5  3.4 66.4  5.5 
aKM and VMAX were measured as described in ‘Experimental’. 
bError represents 1 S.E. 
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Table 6. Michaelis-Menten kinetics of Spectrozyme Th hydrolysis by thrombin in presence 
of SBT.a 
 
[SBT] 
(M) 
Overnight incubation at 25°C Two hours incubation at 37°C 
KM VMAX KM VMAX 
(M) (mAU/min) (M) (mAU/min) 
0 9.50  1.90b 80.79  5.13 7.69  2.21 85.76  7.35 
0.36 11.14  2.71 79.95  6.51 ND c ND 
0.63 7.67  1.27 68.84  3.35 6.73  2.54 72.35  8.68 
1.53 ND ND 2.17  0.80 29.56  1.97 
1.80 3.15  0.50 34.71  1.17 ND ND 
3.60 3.07  0.60 18.81  0.77 2.65  0.62 24.74  1.13 
9.90 ND ND 1.92  0.65 14.71  0.87 
aKM and VMAX were measured as described in ‘Experimental’. 
bError represents 1 S.E. 
cND: not determined  
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Table 7. Inhibition of thrombin by SBD in presence of hirugen analog HirP, porcine 
heparin, heparin octasaccharide or γ’fibrinogen peptide.a 
 
 IC50 (μM) YM Y0 ΔY HS 
[HirP] nM      
0 5.3  0.03b 0.99  0.02 0.59  0.01 0.40  0.01 2.3  0.3 
3 7.8  0.05 0.99  0.01 0.45  0.04 0.54  0.05 2.1  0.3 
5 4.0  0.04 1.02  0.05 0.39  0.07 0.63  0.14 2.2  0.6 
15 3.1  0.03 1.02  0.05 0.44  0.04 0.58  0.08 2.2  0.6 
30 3.4  0.03 1.03  0.04 0.48  0.04 0.55  0.07 2.6  0.7 
[H8] μM      
0 2.7  0.01 0.98  0.01 0.50  0.02 0.48  0.02 8.4  2.0 
1 2.8  0.01 0.98  0.01 0.56  0.01 0.42  0.01 5.1  0.9 
3 3.4  0.02 1.0  0.02 0.55  0.03 0.45  0.03 3.4  0.8 
10 3.7  0.03 0.99  0.02 0.52  0.03 0.47  0.04 1.9  0.3 
[UFH] μM      
0 8.8  0.2 0.99  0.01 0.52  0.01 0.47  0.02 2.7  0.4 
4.8 10.6  0.4 1.00  0.03 0.56  0.03 0.44  0.03 2.4  0.8 
11.2 21.8  0.4 0.95  0.03 0.46  0.05 0.49  0.07 1.7  0.6 
20.6 26.3  0.2 0.98  0.02 0.50  0.03 0.48  0.03 2.1  0.4 
48 36.1  0.2 0.95  0.02 0.41  0.04 0.54  0.06 2.7  0.7 
[FibP] μM      
0 8.0  0.4 1.04  0.06 0.63  0.03 0.41  0.05 2.9  1.2 
0.2 39.2  0.8 1.01  0.02 0.69  0.04 0.32 0.02 1.6  0.4 
0.65 65.6 ± 0.4 0.99 ± 0.01 0.55 ± 0.02 0.44 ± 0.02 8.0 ± 1.5 
2 84.9  0.2 1.00  0.01 0.54  0.01 0.46  0.01 3.5  0.4 
6.5 117.8  0.2 0.97  0.02 0.44  0.04 0.53  0.06 3.1  0.8 
 
aThe IC50, HS, YM, YO values were obtained following non-linear regression analysis of direct inhibition of 
human thrombin in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2, and 0.1% 
polyethylene glycol (PEG) 8000 at 25 °C. Inhibition was monitored through spectrophotometric 
measurement of residual thrombin activity (see ‘Experimental’). 
 bErrors represent  1 S. E. 
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Table 8. Inhibition of thrombin by SBT in presence of hirugen analog HirP, porcine 
heparin, heparin octasaccharide or γ’fibrinogen peptide.a 
 
[Competitor] IC50 (µM)  Y0 YM ∆Yb 
0 µM 0.68  0.01c 13  4 110  4 97  6 
Hirugen Analog     
3 nM 0.76  0.02 46  5 109  5 63  7  
5 nM 0.63  0.01 47  3 108  4 61  5 
15 nM 0.56  0.02 51  3 111  7 60  8 
Porcine Heparin     
4.2 µM 1.00  0.02 19  6 110  5 91  8  
12.8 µM 2.44  0.04 6  5 107  4 101  6 
25.0 µM 4.70  0.07  2  5  105  3 103  6 
42.6 µM 6.10  0.09 3  5 104  2 101  5 
Heparin Octasaccharide H8      
1.0 µM 1.71  0.04 24  7 105  3 81  8 
3.0 µM 1.31  0.03 33  6 105  5 72  8 
10 µM 1.55  0.04 40  4 107.3  5 67  6 
20 µM 2.24  0.07 35  7 105  4 70  8 
γ’Fibrinogen peptide     
0.2 μM 1.31  0.03 6  8 108  4 102  9 
0.65 μM 1.03  0.02 16  5 107  5 91  7 
2 μM 0.92  0.03 23  5 114  9 91  10 
6.5 μM 0.90  0.03 29  4 119  11 90  12 
 
a Inhibition studies were performed in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM 
CaCl2 and 0.1 % PEG 8000 in PEG 20,000-coated acrylic cuvette. Spectrozyme TH was used as substrates 
and the residual enzyme activity in the presence of the trimer was assessed by measuring the initial rate of 
substrate hydrolysis at 405 nm after overnight incubation. Logistic equation 1 was used to fit the dose 
dependence of the residual enzyme activity to obtain log IC50, Y0, and YM values whereas HS were fixed to 
1. See Methods for details. 
b difference between YM and Y0. 
c represents 1 ± S.E. 
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Table 9. Inhibition parameters for SBD inhibiting recombinant wild-type and mutant 
thrombins at pH 7.4 and 25 °C.a 
 
Thrombin 
Mutants IC50 (μM) YM Y0 ΔY HS 
WT 5.5  0.02b 1.01  0 .02 0.73  0.01 0.27  0.01 6.4  1.3 
R93,97,101A 5.0  0.09 1.01  0.06 0.28  0.05 0.73  0.17 2.1  0.9 
R169A 6.1  0.04 1.00  0.01 0.68  0.01 0.32  0.01 3.3  0.8 
R173A 121  1.2 1.01  0.02 0.47  0.03 0.55  0.05 2.8  0.7 
R175A 5.9  0.02 1.00  0.01 0.60  0.01 0.40  0.01 6.3  1.0 
K235A 9.0  0.04 0.99  0.01 0.64  0.02 0.35  0.02 6.6  1.9 
 
aThe IC50, HS, YM, YO values were obtained following non-linear regression analysis of direct inhibition of 
human thrombin in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2, and 0.1% 
polyethylene glycol (PEG) 8000 at 25 °C (see ‘Experimental’). 
bErrors represent  1 S. E. 
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Table 10. Inhibition parameters for SBT of S2238 hydrolysis by recombinant wild-type and 
mutant thrombins at pH 7.4 and 25 °C.a 
 
Thrombin 
Mutants IC50 (µM) YM Y0 ∆ Yb 
WT 0.261  0.08c 108  5 40  4 68  6 
R93A 0.169  0.03 109  4 31  3 78  5 
R97A 0.243  0.10 116  9 44  5 72  10 
R101A 0.212  0.03 105  4 38  3 67  5 
R126A 0.222  0.07 108  5 28  4 80  6 
R165A 0.249  0.06 105  4 42  2 63  5 
K169A 0.235  0.07 119  7 36  3 83  8 
R173A 0.292  0.10 110  7 23  7 87  10 
R175A 0.286  0.13 110  9 52  4 58  10 
R233A 0.789  0.2 103  2 37  4 66  5 
K235A 0.294  0.06 105  3 42  3 63  4 
K236A 0.247  0.09 119  9  40  3 79  10 
K240A 0.308  0.08 107  3 41  4 66  5 
R93,97A 0.190  0.01 120  10 32  5 88  21 
R93,101A 0.641  0.01  113  7 38  3 75  11 
R97,101A 0.472  0.01 106  5 26  3 80  13 
R93,97,101A 3.470  0.07 103  2 31  7 72  18 
 
aThe IC50, YM, and YO values were obtained following non-linear regression analysis of direct inhibition of S2238 
hydrolysis by human thrombin in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2, and 
0.1% polyethylene glycol (PEG) 8000 at 25 °C and overnight incubation whereas HS were fixed to 1. (see 
‘Experimental’). 
b difference between YM and Y0. 
c represents 1 ± S.E. 
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Figure Legends 
Figure 24. Structure of sulfated benzofuran dimers and trimers. A) Concept behind designing 
small molecule benzofuran-based inhibitors from polymeric LMWLs. B) SBD and 
SBT studied in this work. 
Figure 25. Michaelis-Menten kinetics of Spectrozyme TH hydrolysis by human thrombin in 
presence of SBD. The initial rate of hydrolysis at various substrate concentrations was 
measured spectrophotometrically in pH 7.4 buffer after 10 min incubation. Solid lines 
represent non-linear regressional fits to the data by the standard Michaelis-Menten 
equation to yield KM and VMAX. 
Figure 26. Michaelis-Menten kinetics of Spectrozyme TH hydrolysis by human thrombin in 
presence of SBT. The initial rate of hydrolysis at various substrate concentrations was 
measured spectrophotometrically in pH 7.4 buffer after (A) Overnight incubation at 
25°C and (B) Two hours incubation at 37 °C with different trimer concentrations. Solid 
lines represent non-linear regressional fits to the data by the standard Michaelis-Menten 
equation to yield KM and VMAX. 
Figure 27. Competitive effect of the hirudin peptide HirP on the inhibition of human plasma 
thrombin by SBD. (A) Residual thrombin activity was measured through Spectrozyme 
TH hydrolysis in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM 
CaCl2 and 0.1 % polyethylene glycol (PEG) 8000 at 25 °C in the presence of 0 to 48 
nM of HirP. Solid lines represent fits using the logistic equation 1 to obtain the apparent 
IC50, as described in ‘Experimental’. (B) Graphical comparison of the predicted 
(shaded bars) and observed (unshaded bars) IC50,app obtained from Dixon-Webb 
relationship (equation 2) for HirP and SBD competition.  
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Figure 28. Competitive effect of HirP on the inhibition of human thrombin by SBT. (A) Residual 
thrombin activity was measured through Spectrozyme TH hydrolysis in 20 mM Tris-
HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2 and 0.1 % polyethylene 
glycol (PEG) 8000 at 25 OC and overnight incubation in the presence of 0 – 15 nM of 
HirP. Solid lines represent fits using the logistic equation 1 to obtain the apparent IC50 
and ∆Y, while HS was fixed to 1 as described in ‘Experimental’. (B) Graphical 
comparison of the predicted (shaded bars) and observed (unshaded bars) IC50,app 
obtained from the Dixon-Webb relationship (equation 2) for HirP and SBT competition.  
Figure 29. Competitive effect of heparin octasaccharide H8 (A) and unfractionated heparin UFH 
(B) on the inhibition of human plasma thrombin by SBD in 20 mM Tris-HCl buffer, 
pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2 and 0.1 % polyethylene glycol (PEG) 
8000 at 25 OC and 10 min incubation in the presence of 0 to 10 μM H8 and 0 to 48 M 
UFH. Solid lines represent fits using the logistic equation 1 to obtain the apparent IC50, 
as described in ‘Experimental’. 
Figure 30. Graphical comparison of the predicted (shaded bars) and observed (unshaded bars) 
IC50,app obtained from Dixon-Webb relationship (equation 2) for both (A) H8 and (B) 
UFH competition with SBD.  
Figure 31. (A) Competitive effect of the γ’-fibrinogen peptide (FibP) on the inhibition of human 
plasma thrombin by SBD in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 
2.5 mM CaCl2 and 0.1 % polyethylene glycol (PEG) 8000 at 25 OC in the presence of 
0 to 6.5 μM of the peptide. Solid lines represent fits using the logistic equation 1 to 
obtain the apparent IC50, as described in ‘Experimental’. (B) Comparison of the 
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predicted (shaded bars) and observed (unshaded bars) IC50,app. Obtained from the 
Dixon-Webb relationship (equation 2) for FibP and SBD competition. 
Figure 32. (A) Competitive effect of UFH on the inhibition of human plasma thrombin by SBT in 
20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2 and 0.1 % 
polyethylene glycol (PEG) 8000 at 25 OC in the presence of 0 – 42.6 μM UFH after 
overnight incubation. Solid lines represent fits using the logistic equation 1 to obtain 
the apparent IC50 and ∆Y while HS was fixed to 1, as described in ‘Experimental’. (B) 
Graphical comparison of the predicted (shaded bars) and observed (unshaded bars) 
IC50,app obtained from the Dixon-Webb relationship (equation 2) for UFH and SBT 
competition.  
Figure 33. Competitive effect of H8 (A) and FibP (B) on the inhibition of human plasma thrombin 
by SBT in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2 
and 0.1 % polyethylene glycol (PEG) 8000 at 25 OC and overnight incubation in the 
presence of 0 – 20 μM H8 or 0 – 6.5 μM FibP. Solid lines represent fits using the logistic 
equation 1 to obtain the apparent IC50 and ∆Y while HS was fixed to 1, as described in 
‘Experimental’. 
Figure 34. Graphical comparison of the predicted (shaded bars) and observed (unshaded bars) 
IC50,app obtained from the Dixon-Webb relationship (equation 2) for both (A) H8 and 
(B) FibP competition with SBT.  
Figure 35. Dose-response profiles for SBD inhibition of recombinant wild type and mutant 
thrombins in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2 
and 0.1 % polyethylene glycol (PEG) 8000 at 25 OC. Solid lines represent sigmoidal 
dose-response fits of equation 1. 
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Figure 36. Effect of alanine scanning of the basic residues in thrombin exosite 2 on the direct 
inhibition potency of SBT. The ratio of IC50 values of the mutant to that of recombinant 
wild-type is shown. Inset shows the dose-response profiles for SBT inhibition of 
recombinant wild type compared to Arg233Ala and Arg93,97,101Ala mutants using 
S2238 as substrate in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 
mM CaCl2 and 0.1 % polyethylene glycol (PEG) 8000 at 25 OC. Solid lines represent 
sigmoidal dose-response fits of equation 1 to obtain the apparent IC50 and ∆Y while HS 
was fixed to 1, as described in ‘Experimental’.  
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Chapter 5: Detailing the Nature of Molecular Interaction between Low 
Molecular Weight Lignins and Thrombin 
    5.1. INTRODUCTION 
Macromolecules are known by the complex nature of their interactions. Characterizing 
their binding to proteins, crystallizing their complexes and understanding their binding on the 
molecular level is more complicated than small drug-like molecules. While some macromolecules 
have been successfully co-crystalized with thrombin, understanding the way they interact is far 
less investigated. Taking thrombin as our focus, new theories are introduced each day that prove 
the intricacy involved in its interactions. Another complication is the presence of the two anion-
binding exosites that engage different ligands, some of which bind to both sites. For example, the 
GpIb receptor present on the platelet surface interacts with exosite 2. However a recent study has 
shown that the receptor binds to thrombin in a model where each of the two exosites are involved 
in binding a different GpIb molecule.67 The energetic linkage between the two exosites when 
ligands bind is also a well-known controversial issue. For thrombin there are studies that support 
strongly linked binding85 and other studies proving that their binding is mutually exclusive.83 
LMWLs are no exception. As the first macromolecules to inhibit thrombin in an allosteric 
way by exclusively engaging exosite 2, it was important to understand how they evoke their action. 
The polymeric nature of these molecules complicates the process of co-crystallizing them with 
thrombin. This makes it difficult to understand the nature of their interaction from structural data. 
A way to work around this obstacle is to obtain insight about their binding from other biochemical 
techniques. Heparin is a good model whose interaction is well characterized by such studies. It 
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also serves as a good example due to the fact that sulfated LMWLs were initially designed as 
heparin mimetics.  
A multi-disciplinary approach with three major aspects was designed to dissect the 
interactions of two LMWLs, CDSO3 and FDSO3, with thrombin. The first aspect is to characterize 
the electrostatics of binding using salt-dependency studies so as to understand the involvement of 
ionic and non-ionic interactions in the binding. Ionic interactions mainly invoke charge pairs and 
salt bridges, while non-ionic ones involve hydrophobic interactions and hydrogen bond formation. 
The two LMWLs are fairly similar in origin and structure, yet analysis of the physicochemical 
properties showed that FDSO3 had a higher charge density than CDSO3, which offers a better 
chance for FDSO3 to form ionic interactions.90 Another difference is the presence of a hydroxyl 
group in caffeic acid, the monomeric unit for CDSO3, that is replaced by a methoxy group in ferulic 
acid, the building block for FDSO3. This difference may allow CDSO3 to better hydrogen bond 
with thrombin. Detailed analysis of the contribution of these forces would elaborate more on the 
nature of the interaction of these molecules and their similarity to heparin. 
The second goal is to characterize the thermodynamic profile of these molecules. Heparin 
itself is not well characterized in this regard and it would be interesting to compare the behavior 
of the three polymers. The emerging significance of thermodynamics in drug discovery and more 
importantly in lead optimization has received considerable attention in literature.125 The binding 
of a ligand to its target occurs spontaneously only when the free energy of binding (ΔG) is 
favorable. This energy is the sum of two terms, enthalpic ΔH and entropic –TΔS, which can have 
similar or opposite signs, potentially leading to different thermodynamic signature for each binding 
event. The binding can be either enthalpy-driven or entropy-driven. Understanding the 
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contribution of each term to the binding affinity allows their optimization to obtain better ligands 
with higher affinity and/or specificity to their targets.  
The last aspect is to understand the linkage between sodium and LMWLs binding to 
thrombin. Sodium is well-documented to shift the enzyme to a fast (proteinase-like) form. 
Removal of sodium has been shown to shift the equilibrium back to the slow (zymogen-like) 
form.77 One of the reasons that LMWLs inhibit thrombin could be the displacement of sodium and 
the concomitant shift to the catalytically less efficient thrombin. Yet, little is known about how the 
activation of thrombin by sodium affects exosite 2. Studying the effects of changing sodium 
concentration on the binding affinity of LMWLs may also point out the novelty of these molecules 
as probes for investigating the binding in thrombin exosite 2. 
The three aspects are different in methodology, yet they draw one broad picture about the 
nature of interaction of these molecules with thrombin. They will be handled individually in the 
following sections, then a general conclusion for all the results will be presented at the end of the 
chapter. 
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5.2. Electrostatics of Binding of LMWLs and Thrombin 
Heparin and related molecules follow the polyelectrolyte theory of binding for charged 
polymers.126,127 The theory postulates that interaction of charged polymers with proteins results in  
displacement of large numbers of counter-ions. This leads to an increase in entropy that has a 
significant contribution to the free energy of binding. Thus, the increase in the ionic strength or 
salt concentration in the medium leads to weakening of the binding. This phenomena was used 
extensively for studying heparin interactions.126-130 The nature of LMWLs as polyelectrolytes 
makes it feasible to use the same theory for studying their interaction with thrombin. Unfortunately, 
changing the concentration of sodium in the medium has another important effect on thrombin that 
can affect the results obtained from such studies. It is well established now that sodium binding 
activates thrombin catalytic efficiency, while it also leads to conformational changes that have 
global effects on the enzyme structure,23,27,28,131,132 which may lead to changing the binding affinity 
of LMWLs.  
To avoid the structural and catalytic side effects of changing sodium concentration on 
thrombin, we resorted to an active site labeled, inhibited form of the enzyme. Using a fluorescein 
labeled inhibitor D-Phe-Pro-Arg-CH2Cl (FPR) that irreversibly alkylates His57 of the catalytic 
triad achieves two important goals. First, the fluorescence dye reports any structural changes that 
occur near the environment of the active site. As our molecules bind to exosite 2, they are 
postulated to induce a conformational change in the active site that the dye will be able to report, 
and from which the KD can be calculated. The second goal is that inhibiting thrombin locks the 
structure of the enzyme in one conformation and thus preventing sodium from changing the 
structure of the enzyme as it would do with the free form. This will restrict the effects of increasing 
the sodium concentration in the medium to only the electrostatic disturbance of LMWLs binding. 
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The same technique was applied before for studying the salt dependancy of thrombin – 
thrombomodulin interaction.133 
5.2.1. EXPERIMENTAL 
5.2.1.1. Proteins, LMWLs, Chemicals and Reagents.  
Sulfated dehydropolymers CDSO3 and FDSO3 (Figure 37) were synthesized in two steps 
from 4-hydroxycinnamic acid monomers, caffeic acid and ferulic acid, using chemo-enzymatic 
synthesis.49 Active site inhibited thrombin labeled with fluorescein (fFPR-Th) was purchased from 
Haematologic Technologies (Essex Junction, VT). Stock solutions of thrombin were prepared in 
20 mM Tris-HCl buffer (pH 7.4). All other chemicals were analytical reagent grade from either 
Sigma Chemicals (St. Louis, MO) or Fisher (Pittsburgh, PA) and used as such.  
5.2.1.2. Thrombin – LMWLs Binding Study.  
fFPR-Th was freshly prepared from stock solution to get a final concentration of 50 nM in 
20 mM Tris-HCl buffer, pH 7.4, containing 150 mM NaCl, 2.5 mM CaCl2 and 0.1 % polyethylene 
glycol (PEG) 8000 at 25 °C in a fluorescence quartz cuvette. Experiments were done using a QM4 
fluorometer (Photon Technology International, Birmingham, NJ) thermostated with a Lauda-
Brinkmann circulating water bath. Equilibrium dissociation constants (KD) for either CDSO3 or 
FDSO3 – thrombin complex were determined by titrating the polymer into a solution of fFPR-Th 
and monitoring the decrease in the fluorescence at λemission = 525 nm (λexcitation = 490 nm). The 
studied molecules did not have any absorbance at the emission wavelength to interfere with the 
readings (Figure 38). The slit widths on the excitation and emission side were 1 and 2 mm, 
respectively. The decrease in fluorescence signal upon complex formation was fit to the quadratic 
equilibrium binding equation 3 to obtain the KD of interaction: 
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߂ܨ
ܨఖ ൌ 	
߂ܨ௠௔௫	ܳ െ	ඥܳଶ	 െ 4	 ൈ 	ሾ݂ܨܴܲ െ ݄ܶሿఖ 	ൈ	 ሾܮܯܹܮሿఖ
ܨఖ																																						2 ൈ ሾ݂ܨܴܲ െ ݄ܶሿఖ  
ܳ ൌ ሾ݂ܨܴܲ െ ݄ܶሿఖ ൅	ሾܮܯܹܮሿఖ ൅ ܭ஽          (equation 3) 
where ΔF is the change in fluorescence due to formation of the complex following each addition 
of inhibitor [LMWL]ο from the initial fluorescence Fο, and ΔFmax represents the maximum change 
in fluorescence observed on saturation of fFPR-Th. A binding stoichiometry of 1:1 was assumed 
for the interaction. 
5.2.1.3. Salt Dependence of LMWLs – Thrombin Interaction.  
The contribution of ionic and non-ionic binding energies to thrombin – LMWLs interaction 
was determined by measuring the KD,obs of the binding in buffers with increasing salt 
concentration. NaCl was added to 20 mM Tris-HCl buffer, pH 7.4, containing 2.5 mM CaCl2 and 
0.1 % polyethylene glycol (PEG) 8000 in concentrations ranging from 100 – 300 mM using 50 
nM fFPR-Th. The plot of log KD,obs versus log [Na+] yields a linear relationship (equation 4) that 
can be used to analyze the ionic and non-ionic forces involved in binding. The equation also 
determines the number of ionic interactions formed between the protein and the polyelectrolyte: 
logܭ஽,௢௕௦ ൌ logܭ஽,ேூ ൅ ܼ߰ logሾܰܽାሿ            (equation 4) 
where KD,obs is the recorded equilibrium dissociation constant, which is a summation of ionic and 
non-ionic forces, KD,NI is the equilibrium dissociation constant for the non-ionic component of 
binding (at 1 M Na+), Z is the actual number of ionic interactions formed between the protein and 
the polyelectrolyte during binding and ψ is the fraction of counter-ions attached to each charge on 
the polyelectrolyte and released to solution after binding to protein. The value of ψ for heparin has 
been experimentally determined to be ~0.8,23,132 and the same value was used for LMWLs.28 Thus, 
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the straight line obtained will have a slope of Zψ and an intercept of log KD,NI from which the free 
energy component of non-ionic interaction can be determined according to Gibbs free energy (ΔG) 
relationship,  
ΔG = – RT ln KA            (equation 5) 
where R is the gas constant, T is absolute temperature and KA is the equilibrium association 
constant. 
5.2.2. RESULTS 
5.2.2.1. LMWLs Bind Thrombin with High Affinity and Cause a 
Conformational Change in Thrombin Active Site.  
Binding of CDSO3 and FDSO3 with fFPR-Th resulted in a decrease in fluorescence to 
~30% of the initial value (Figure 39). This reflects the changes happening in the active site 
environment, where the label is covalently attached after LMWLs bind at exosite 2. The decrease 
in fluorescence could be fitted to the quadratic equation 3 to obtain the affinity of interaction. The 
KD was found to be 75 nM for CDSO3 and 300 nM for FDSO3 at pH 7.4, 25 °C, and I = 0.15. This 
corresponds to binding energies of -9.75 kcal/mol for CDSO3 and -8.93 kcal/mol for FDSO3. This 
is a significantly high affinity for sulfated non-carbohydrate polymers interacting with proteins, 
which renders these molecules potent thrombin ligands.134-136 
5.2.2.2. CDSO3 and FDSO3 Show Different Contributions of Ionic and Non-
ionic Binding Energies.  
The dissociation constants for both polymers were studied under variable salt 
concentrations using spectrofluorometric titration of the enzyme solution with the ligands. The 
KD,obs was found to increase with increasing sodium concentration for CDSO3 and FDSO3 (Table 
 
 
115 
 
11, Figure 40) as observed before for heparin and heparin pentasaccharide interaction with 
antithrombin.23,132 According to the polyelectrolyte theory, the non-ionic component of the binding 
KD,NI can be obtained from the intercept of the linear plot of log KD versus log [Na]+ (Figure 41), 
while the slope can be used to calculate Z, the actual number of ion pair interactions involved in 
the complex formation. 
The slopes of the lines for CDSO3 and FDSO3 plots were 1.66 and 3.65, respectively. This 
was the first major difference between the two polymers.  Assuming ψ to be 0.8, the slopes indicate 
that CDSO3 forms only 2 ion-pair interactions, while FDSO3 forms 4-5 ionic interactions with 
thrombin. This result shows that FDSO3 behaves more like heparin in having multiple ionic 
interactions with thrombin.28 The intercept for CDSO3 came at a large value of -5.78, which 
corresponds to a large KD,NI of 1.66 μM. Using equation 5 to estimate the ΔGNI gives a value of 
7.91 kcal/mol which is almost 81% of the total binding energy of the complex formation, 
highlighting the importance of non-ionic forces in CDSO3 interaction with thrombin. On the other 
hand, FDSO3 had an intercept of -3.35, which represented a KD,NI of 445.76 μM. This translates to 
ΔGNI of -4.59 kcal/mol which represents 51% of the total binding energy and indicates that FDSO3 
enjoys a balanced ionic and non-ionic contributions to its binding to thrombin.  
5.2.3. DISCUSSION 
LMWLs are structurally and mechanistically distinct from any thrombin inhibitor known 
to date. Although they were initially designed as heparin mimetics, the molecules were found to 
inhibit thrombin directly in an antithrombin independent manner. Moreover, it was found that these 
polymers act allosterically through interacting with exosite 2. The affinity of those polymers was 
found to be in the nanomolar range, which is quite potent compared to similar non-carbohydrate 
sulfated ligands interacting with coagulation enzymes and serpins.134-136 Measuring the affinity 
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using labeled active site inhibited thrombin puts the enzyme in a locked conformation that is not 
affected by the variation in sodium concentration used to assess the salt dependency. The change 
in fluorescence after LMWLs – thrombin complex formation indicates a change in the environment 
of the active site that is arising from a conformational change induced by the inhibitors’ binding 
and leads to impairing the catalytic efficiency of the enzyme.  
Plotting log KD,app versus log [Na+] displayed a linear relationship, which proves that 
LMWLs follow the polyelectrolyte theory. From the intercept and slope of the line it was clear that 
CDSO3 and FDSO3 have distinct profiles of binding energies. While CDSO3 formed only 2 ion-
pair interactions with thrombin and the majority of the affinity (~80%) came from non-ionic forces, 
FDSO3 had more significant salt dependence of KD that resembled the heparin profiles.28 The plot 
indicated that 4 – 5 ion pairs are formed during its complex formation with thrombin and that the 
polymer enjoyed balanced ionic and non-ionic forces for binding.  
The results are expected based on the structural differences between the two related 
polymers. CDSO3 had side chains of hydroxyl groups that are probably involved in hydrogen bond 
formation with the basic residues in exosite 2, which would significantly increase the non-ionic 
contribution to ΔG. This is also corroborated by site-directed mutagenesis data obtained earlier for 
both polymers. CDSO3 had only two key residues important to its binding, Arg93 and Arg175, and 
mutating them to Ala led to reducing the inhibition potency by 7 – 8 fold. The formation of only 2 
ion-pairs during complex formation reaffirms that fewer ionic interactions may generate high 
affinity for thrombin and points to Arg93 and Arg175 as the two residues involved in the ion-pair 
formation. On the other hand, FDSO3 inhibition was not affected by any single point mutation of 
all arginines and lysines in exosite 2. Double and triple mutants showed progressively impaired 
inhibition that reached almost 50-fold with triple mutant Arg93,97,101Ala. This highlights the fact 
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that FDSO3 makes multiple ionic interactions with exosite 2 residues such that knocking down one 
residue at a time had no effect on its affinity. The results were clarified with the salt dependency 
data that showed 4 – 5 ion pairs formed in FDSO3 – thrombin complex.  
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Table 11. The salt dependency of KD of CDSO3 and FDSO3 was monitored by measuring the 
KD using fluorescence titration of fFPR-Th in buffers of increasing sodium 
concentrations. 
 
 
 
 
 
 
 
 
 
 
aThe KD was obtained following analysis of binding to 50 nM fFRP-Th in 20 mM Tris buffer, pH 7.4, 
containing  100 - 300 mM NaCl, 2.5 mM CaCl2, and 0.1% polyethylene glycol (PEG) 8000 at 25 °C (see 
‘Experimental’). 
b ND: not determined. 
  
[Na+] (M) 
KD (M)a 
FDSO3 CDSO3 
0.100  0.12 × 10‐6  ND 
0.150  0.30 × 10‐6  0.76 × 10‐7 
0.200  1.36 × 10‐6  1.09 × 10‐7 
0.250  3.18 × 10‐6  1.60 × 10‐7 
0.300  NDb  2.40 × 10‐7 
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Figure Legends 
Figure 37. The two polymeric chains studied, CDSO3 and FDSO3, with possible linkage types 
shown shaded. Main structural difference in substitution R which may be either –OH 
or –OSO3Na in CDSO3 or –OCH3 in FDSO3.  
Figure 38. Emission scan of CDSO3 (1 μM), FDSO3 (1 μM) and fFPR-Th (200 nM) in 20 mM 
Tris-HCl buffer (pH 7.4) at 25 °C. Excitation was set at 490 nm and emission scanned 
from 500 – 600 nm.  
Figure 39. Binding of fFPR-Th to CDSO3 and FDSO3, where the fluorescence of 50 nM enzyme 
was monitored in 20 mM Tris buffer, pH 7.4, containing 150 mM NaCl, 2.5 mM CaCl2 
and 0.1 % polyethylene glycol (PEG) 8000 as it was titrated by a stock solution of 5 μM 
LMWLs at 25 °C in a fluorescence quartz cuvette. Solid lines represent fits using 
equation 3 to obtain the apparent KD as described in ‘Experimental’. 
Figure 40. Salt dependency of LMWLs interaction with fFPR-Th. The fluorescence of 50 nM 
enzyme was monitored in 20 mM Tris buffer, pH 7.4, containing increasing 
concentrations of NaCl (100 – 300 mM), 2.5 mM CaCl2 and 0.1 % polyethylene glycol 
(PEG) 8000 as it was titrated by a stock solution of 5 μM CDSO3 (A) or FDSO3 (B) at 
25 °C in a fluorescence quartz cuvette. Solid lines represent fits using equation 3 to 
obtain the apparent KD as described in ‘Experimental’. 
Figure 41. A plot for CDSO3 and FDSO3 where data of log KD obtained from fluorescence 
titrations where used versus log [Na]+. Solid lines represent linear fits using equation 4 
to obtain the KD,NI and Z as described in ‘Experimental’. 
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Figure 37 
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Figure 39 
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Figure 40A 
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Figure 40B 
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Figure 41 
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5.3. Thermodynamics of Binding of LMWLs and Thrombin 
Acquiring thermodynamic parameters is done using three major methods, either directly 
through isothermal titration calorimetry (ITC), differential scanning calorimetry (DSC) or 
indirectly through thermodynamic calorimetry, which does not use a calorimeter.137 DSC measures 
heat capacity (Cp) changes as a function of temperature, while ITC is the most comprehensive tool 
since it measures the heat uptake/release during molecular interaction. This gives a direct measure 
of the enthalpy of binding (ΔH). It also measures the amount of free or bound ligand, which is 
used to determine the equilibrium binding constant KA (inverse of the dissociation constant KD). 
From that information, ΔG and other thermodynamic binding parameters like entropy (ΔS) are 
estimated, and if done at different temperatures, allow the calculation of ΔCp.  
Heat capacity is one of the lesser understood, yet rich in information, thermodynamic 
parameters. With more than a dozen definitions, the most general one (equation 6) would be the 
amount of heat energy the protein requires to raise its temperature: 
ܥ݌ ൌ 	 ௗுௗ்    (equation 6) 
Other commonly used equation is: 
ܥ݌ ൌ ܶ	 ௗௌௗ் ൌ 	െܶଶ 	
ௗమீ
ௗ்మ     (equation 7) 
Integrating these equations assuming constant heat capacity gives rise to the modified Gibbs-
Helmholtz, or the integrated van’t Hoff equation: 
߂ܩ ൌ െܴܶ	݈݊ܭ஺ ൌ 	߂ܪ െ ܶ߂ܵ ൌ 	߂ܥ݌	ሺܶ െ ுܶ െ ܶ	݈݊ ்்ೄሻ  (equation 8) 
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TH and TS are specific temperature values, where the binding enthalpy and entropy vanishes, 
respectively. TH in particular is the absolute temperature where the equilibrium dissociation 
constant assumes its minimum value. This equation has been applied before to thrombin 
interactions with several of its natural substrates like hirudin and thrombomodulin, and in multiple 
other biological systems as well, yet it has seldom been used to analyze a protein – polyelectrolyte 
interaction.138-141 
Heat capacity changes in protein interactions received significant attention almost 40 years 
ago. The interpretation of the magnitude and sign of ΔCp is a complex process that implicates 
protein folding/unfolding and binding to small ligands as well as macromolecules. This is simply 
the difference between the heat capacity of the complex and heat capacity of its individual 
components. If the unreacted partners require more heat energy to raise their temperature (i.e., high 
heat capacity) compared to the complex formed, then the difference (ΔCp) will be negative. The 
sign of ΔCp could be positive or negative according to the type of interaction between the protein 
and its binding partner, whether a macromolecule or a small ligand. Protein folding, for example, 
shows a large negative ΔCp.137  
Heat capacity changes are attributed to changes in the ordered molecular water layer around 
the protein and its partner, which have lower kinetic energy than bulk water, allowing it to absorb 
more heat energy without raising its temperature. When, for example, two hydrophobic surfaces 
are buried in the binding process, the surface area covered by water in the complex is less than the 
individual partners, this is known as the hydrophobic effect. This lower number of water molecules 
can thus absorb less heat energy and the complex as a whole will have lower heat capacity. This is 
why negative ΔCp is often noted as the hallmark of hydrophobic interactions.142 
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In this work we used thermodynamic calorimetry where we calculate the thermodynamic 
parameters of LMWLs interaction with thrombin by studying the dependence of the binding on 
temperature. This technique tracks the changes in KD at different temperatures using fluorescence. 
Fitting the data to the integrated van’t Hoff equation, one can obtain ΔCp of binding, and calculate 
ΔH and ΔS at each studied temperature. The electrostatic forces governing the binding of these 
polyelectrolytes are not common in protein – protein or protein – ligand interactions that mainly 
involve burial of hydrophobic surfaces and negative heat capacity change (ΔCp). Few cases of 
polyelectrolyte thermodynamic investigation have been documented in the literature,27 so 
unfractionated heparin was also studied under the same conditions as a prototypic example. 
5.3.1. EXPERIMENTAL  
5.3.1.1. Proteins, LMWLs, Chemicals and Reagents.  
Sulfated dehydropolymers CDSO3 and FDSO3 were synthesized in two steps from 4-
hydroxycinnamic acid monomers, caffeic acid and ferulic acid, using chemo-enzymatic 
synthesis.49 Unfractionated porcine heparin (UFH) was purchased from Sigma (St. Louis, MO). 
Active site inhibited thrombin labeled with fluorescein (fFPR-Th) was purchased from 
Haematologic Technologies (Essex Junction, VT). Stock solutions of thrombin were prepared in 
20 mM Tris-HCl buffer (pH 7.4). All other chemicals were analytical reagent grade from either 
Sigma Chemicals (St. Louis, MO) or Fisher (Pittsburgh, PA) and used as such.  
5.3.1.2. Thermodynamics of LMWLs–Thrombin Interaction.  
The thermodynamic parameters of interaction were determined by measuring the KA of the 
binding at different temperatures (5 – 45 °C) in 20 mM Tris-HCl buffer, pH 7.4, containing 100 
mM NaCl, 2.5 mM CaCl2 and 0.1 % polyethylene glycol (PEG) 8000 in a fluorescence quartz 
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cuvette. Experiments were done using a QM4 fluorometer (Photon Technology International, 
Birmingham, NJ) thermostated with a Lauda-Brinkmann circulating water bath. Equilibrium 
dissociation constants (KD) for either CDSO3, FDSO3 or the UFH–thrombin complex were 
determined by titrating the ligand into a solution of fFPR-Th and monitoring the decrease in the 
fluorescence at 525 nm (λex = 490 nm) upon complex formation. The studied molecules did not 
have any absorbance at the emission wavelength to interfere with the readings. The slit widths on 
the excitation and emission side were 1 and 2 mm, respectively. The decrease in fluorescence of 
the complex signal was fit to the quadratic equilibrium binding equation 3 to obtain the KD of 
interaction at different studied temperatures from which KA was calculated. The integrated van’t 
Hoff equation 8 was rearranged to  
ln ܭ஺ ൌ ௱஼೛
എ
ோ 	ቂ
்ಹ
் െ ln ቀ
்ೄ
் ቁ െ 1ቃ    (equation 9) 
A plot of KA versus 1/T yields a non-linear curve; fitting the curve to equation 9 will allow 
the determination of ΔCp, TH and TS. Sigmaplot 8.0 (SPSS, Inc. Chicago, IL) was used to perform 
non-linear curve fitting in which ΔCp, TH and TS were allowed to float. Equation 8 was again 
rearranged to obtain ΔH and ΔS at each studied temperature, where 
߂ܵఖ ൌ ߂ܥ௣ఖ݈݊ ቀ ்்ೄቁ     (equation 10) 
߂ܪఖ ൌ ߂ܥ௣ఖሺܶ െ ுܶሻ     (equation 11) 
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5.3.2. RESULTS 
5.3.2.1. Heparin and LMWLs – Thrombin Interactions Follow an Electrostatic 
Binding Model with a Characteristic Positive ΔCp.  
The thermodynamic parameters for CDSO3, FDSO3 and UFH interaction with thrombin 
were measured using thermodynamic calorimetry. In this technique the KD of binding is measured 
using fluorescence at different temperatures (5 – 45 °C). Active site inhibited thrombin labeled 
with fluorescein (fFPR-Th) was used in the measurements. The decrease in fluorescence due to the 
complex formation was used to obtain the KD for either CDSO3, FDSO3 or UFH binding to 
thrombin at each temperature (Figure 42). This would yield the KD of interaction at different 
studied temperatures, from which KA was calculated (Table 12). Using this information, a plot of 
ln KA versus 1/T was plotted and found to have a characteristic U-shaped curve (Figure 43). The 
integrated van’t Hoff equation 9 was used to calculate ΔCp as well as TH and TS for each of the 
three studied complexes (Table 13). ΔCp of interaction had a positive sign for all interactions 
ranging between 0.98 – 1.26 kcal/K mol. The positive sign indicates that the complex formation 
involves burial of a polar surface area on protein, i.e. exosite 2. 
The enthalpy and entropy of the interaction at each temperature was estimated using 
equations 10 and 11, respectively, for each ligand. There was a large dependence of ΔH and ΔS on 
the temperature of the interaction for all three polymers that caused the values to change signs 
across the temperature range (Table 14). The data show that for CDSO3 and UFH the interaction 
is enthalpically driven only at 5 °C and entropically driven at higher temperatures. FDSO3, on the 
other hand, does not show this inflection except at 30 °C, indicating more favorable enthalpy than 
the other two ligands. At physiological conditions, the interactions for all three polymers are 
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entropically driven. The UFH – antithrombin interaction was shown before to be controlled by 
entropy, linear fitting of van’t Hoff equation was applied to obtain the results.134 
5.3.3. DISCUSSION  
The majority of protein–protein interactions and most of the protein–small ligand 
interactions involve the burial of hydrophobic surface area, which resembles protein folding and 
warrants a negative sign for ΔCp. Very few protein–protein interactions are dominated by 
electrostatic and/or hydrogen bonds, which accompany the burial of polar surfaces of the protein. 
Those reported interactions have a positive ΔCp, like the interaction between xanthine oxidase and 
superoxide dismutase, which reaches almost 3 kJ/mol.K, and was found to be mediated mainly by 
hydrogen bond interactions.144 Likewise, the tetramerization of phosphofructokinase shows a 
similar behavior.145 The same applies for protein – DNA/RNA interactions, such as the binding of 
the translation initiation factor eIF4E to mRNA with ΔCp of 2 kJ/mol.K.146,147 Some ligands, 
including polyelectrolytes like heparin, bind to macromolecules with a similar thermodynamic 
signature, such as heparin binding to cationic cell penetrating peptides (11-89 cal/mol.K)148 or with 
brain natriuretic peptide (1 kcal/mol).149 Heparan sulfate binding to HIV-1 trans-acting activator 
of transcription has similar positive ΔCp value of 135 cal/mol.K150, while the small molecules 
inhibitors of HIV-1 protease had a larger value of 3.2 kcal/mol.K.151  
Another phenomena also complicates the thermodynamic scene, the involvement of water 
in the binding process, which is known to have an important role especially in carbohydrate – 
protein complexes.152-154 Some studies investigating the hydrophobic component of binding found, 
surprisingly, that it was enthalpically driven.155-157 This contradicts the classic view of the 
hydrophobic effect, which predicts that bringing together two hydrophobic partners during binding 
releases the water at the interface to the bulk solvent and renders the whole process entropic. The 
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researchers attributed this behavior to the nature of the binding protein surface that was poorly 
hydrated, thus the enthalpic penalty of breaking the bonds of the few water molecules was 
overcome by the newly formed ligand–protein interactions and resulted in a large enthalpic 
gain.142,156,158  
On the other hand, the release of tightly bound water molecules from the protein binding 
pockets to bulk solvent is accompanied by a favorable entropic gain estimated to be up to 2 
kcal/mol.K at 300 K.159 Thus, in a well hydrated binding surface, the enthalpic loss due to breaking 
of multiple bound water molecules is not compensated by the gain from the newly formed 
interactions with the ligand.  This was established using two models in recent literature, thrombin 
active site binding to a series of inhibitors160 and selectins binding to the tetrasaccharide sialyl 
lewis X.161 The ligand in the former study was termed a “water oligomer” owing to its numerous 
hydroxide groups, yet it was still incapable of compensating for the enthalpic penalty of water 
release resulting in an unfavorable ΔH. It logically follows that the bigger and more polar the 
binding surface, the more hydrated it will be and the larger the enthalpic penalty of binding. 
Another contribution of water is through the formation of internal water networks or 
channels inside the core of the protein that are assumed to transfer allosteric signals between distal 
sites. One such channel was proposed to exist in thrombin connecting the sodium binding site and 
the active site 15 A° apart. Binding of sodium is said to organize the water molecules inside the 
channel leading to signal transmittance that activates thrombin. The ordering of water molecules 
in the channel was suggested to be the reason behind the large negative ΔCp associated with 
sodium binding to thrombin.75 This unexpected thermodynamic signature does not correlate with 
the size of the pocket where sodium binds, and cannot be explained by the burial of hydrophobic 
surface area. Similar behavior was seen in sodium interaction with other serine proteases.76 
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The results obtained here prove that the studied polyelectrolytes CDSO3, FDSO3 and UFH 
have a positive ΔCp and the interaction is indeed entropically driven under physiological 
conditions. The difference between the two studied inhibitors is also clear. While CDSO3 has 
favorable enthalpy only at very low temperatures, FDSO3 has enthalpically driven interaction up 
to 30 °C. This concurs with the fact that FDSO3 had 4 – 5 ion pair interactions formed with 
thrombin versus only 2 for CDSO3, which means it has better bond formation, i.e., more negative 
enthalpy.  
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Table 12. The temperature dependence of the KD of CDSO3, FDSO3 and UFH measured by 
fluorescence titration using fFPR-Th at different temperatures (5 – 45 °C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aThe KD was obtained following analysis of binding to 50 nM fFRP-Th in 20 mM Tris buffer, pH 7.4, 
containing  100 mM NaCl, 2.5 mM CaCl2, and 0.1% polyethylene glycol (PEG) 8000 at variable 
temperatures (278 – 318 K) (see ‘Experimental’). 
b ND: not determined. 
  
Temp (K) 
KD (M)a 
CDSO3 FDSO3 UFH 
278 3.06 × 10-8 0.38 × 10-8 6.80 × 10-8 
283 NDb 0.70 × 10-8 9.82 × 10-8 
288 4.67 × 10-8 2.02 × 10-8 ND 
293 5.15 × 10-8 2.98 × 10-8 10.91 × 10-8 
298 3.22 × 10-8 6.35 × 10-8 8.75 × 10-8 
303 2.51 × 10-8 5.11 × 10-8 4.76 × 10-8 
308 ND 4.11 × 10-8 ND 
313 1.57 × 10-8 ND 2.26 × 10-8 
318 0.53 × 10-8 3.30 × 10-8 ND 
 
 
135 
 
  
Ta
bl
e 
13
. T
he
 v
al
ue
s f
or
 K
D
, K
A
 a
nd
 ΔG
 a
t 2
5 
°C
 a
nd
 th
e 
ΔC
p,
 T
H
 a
nd
 T
S f
or
 C
D
SO
3, 
FD
SO
3 a
nd
 U
FH
 
Li
ga
nd
K
D
 (M
)
K
A
 (M
)
ΔG
 (k
ca
l/m
ol
)
ΔC
p 
(k
ca
l/K
 m
ol
)
T H
 (K
)
T S
 (K
)
C
D
SO
3
3.
22
 ×
 1
0-
8
3.
11
 ×
 1
07
-1
0.
28
0.
98
28
9
27
9
FD
SO
3
6.
35
 ×
 1
0-
8
1.
58
 ×
 1
07
-9
.8
8
1.
26
30
5
29
7
U
FH
8.
75
 ×
 1
0-
8
1.
14
 ×
 1
07
-9
.6
9
1.
03
28
9
28
0
Th
e 
K
D
, K
A
 an
d 
ΔG
 a
re
 th
e 
va
lu
es
 p
re
vi
ou
sl
y 
de
te
rm
in
ed
 a
t 2
5 
°C
 w
hi
le
 ΔC
p,
 T
H
 a
nd
 T
S w
er
e 
ob
ta
in
ed
 fo
llo
w
in
g 
an
al
ys
is
 
of
 K
D
 p
re
vi
ou
sl
y 
ob
ta
in
ed
 v
er
su
s 1
/T
 a
fte
r a
pp
ly
in
g 
eq
ua
tio
n 
9 
(s
ee
 ‘E
xp
er
im
en
ta
l).
 
 
 
136 
 
  
Ta
bl
e 
14
. T
em
pe
ra
tu
re
 d
ep
en
de
nc
e 
of
 th
er
m
od
yn
am
ic
 p
ar
am
et
er
s o
f t
hr
om
bi
n 
in
te
ra
ct
io
n 
w
ith
 C
D
SO
3, 
FD
SO
3 a
nd
 U
FH
 
ΔH
 (k
ca
l/m
ol
)
TΔ
S 
(k
ca
l/K
 m
ol
)
ΔH
 (k
ca
l/m
ol
)
TΔ
S 
(k
ca
l/K
 m
ol
)
ΔH
 (k
ca
l/m
ol
)
TΔ
S 
(k
ca
l/K
 m
ol
)
27
8
-1
0.
92
-1
.3
3
-3
3.
86
-2
3.
02
-1
1.
21
-2
.0
5
28
8
-1
.1
2
8.
60
-2
1.
26
-1
1.
02
-0
.9
1
8.
36
29
3
3.
78
13
.6
9
-1
4.
96
-4
.8
6
4.
24
13
.7
0
29
8
8.
68
18
.8
6
-8
.6
6
1.
41
9.
39
19
.1
2
30
3
13
.5
8
24
.1
2
-2
.3
6
7.
79
14
.5
4
24
.6
4
31
0
20
.4
4
31
.6
2
6.
46
16
.8
9
21
.7
5
32
.5
0
31
8
28
.2
8
40
.3
7
16
.5
4
27
.5
4
29
.9
9
41
.6
8
C
D
SO
3
FD
SO
3
U
FH
Te
m
pe
ra
tu
re
 (K
)
ΔH
 a
nd
 Δ
S 
w
er
e 
ob
ta
in
ed
 a
fte
r 
pr
ev
io
us
 d
et
er
m
in
at
io
n 
of
 Δ
C
p,
 T
H
 a
nd
 T
S 
af
te
r 
ap
pl
yi
ng
 e
qu
at
io
ns
 1
0 
an
d 
11
 (
se
e 
‘E
xp
er
im
en
ta
l’)
. 
 
 
137 
 
Figure Legends 
Figure 42. The temperature dependence of KD for A) CDSO3, B) FDSO3 and C) UFH, using 50 
nM fFPR-Th for CDSO3 and FDSO3 or 200 nM fFPR-Th for UFH in 20 mM Tris buffer, pH 7.4, 
containing  100 mM NaCl, 2.5 mM CaCl2, and 0.1% polyethylene glycol (PEG) 8000 at variable 
temperatures (278 – 318 K) (see ‘Experimental’). 
Figure 43. The temperature dependence of ln KA of binding for CDSO3, FDSO3 and UFH studied 
using fluorescence titration of fFPR-Th in 20 mM Tris buffer, pH 7.4, containing  100 mM NaCl, 
2.5 mM CaCl2, and 0.1% polyethylene glycol (PEG) 8000 at variable temperatures (278 – 318 K) 
(see ‘Experimental’). Solid lines represent regressional fit to equation 9 where ΔCp, TH and TS 
were allowed to float. 
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Figure 42A 
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Figure 42B 
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Figure 42C 
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5.4. Energetic Linkage between Sodium Binding Site and Exosite 2 of 
Thrombin 
Sodium is well known as an allosteric effector for thrombin. It is not a cofactor since the 
enzyme is catalytically active in its absence. Yet, the activity increases significantly after sodium 
binds.54-56,71 This has led to the now famous designation of “slow” and “fast” thrombins.53,60 Fast 
thrombin mainly acts on fibrinogen and PARs, while in the sodium-free form it is better geared 
towards protein C activation.60 Hence, sodium promotes the pro-coagulant functions of thrombin, 
while in its absence, the enzyme initiates its anticoagulant role. Sodium binding has a global effect 
on the structure of the enzyme. The change in intrinsic fluorescence of thrombin was used to study 
the effects of sodium binding. All the nine tryptophans of thrombin were mutated one at a time to 
phenylalanine. Each mutant experienced a change in the fast phase of fluorescence increase, which 
represents the kinetics of Na+ binding to thrombin. This indicated that the conformational change 
is not only restricted to the active site, but it is extended to affect the entire enzyme.72 Similar 
effects were induced by hirudin binding to exosite 1, even in absence of sodium. It was postulated 
that occupancy of either sodium binding site or exosite 1 stabilizes the enzyme, yet to shift 
thrombin to the fully active conformation, both sites need to be occupied.81 
The linkage between sodium binding and the active site, and that between sodium binding 
and exosite 1, or between exosite 1 and the active site is discussed in a number of papers.60,65,78-81 
Contradictory studies were published regarding the connection between exosites 1 and 2, ranging 
from strong linkage85 to mutually exclusive binding.83 Yet, very few studies discuss the interplay 
of exosite 2 with any of these domains. This can be attributed to the fact that beside GAGs, few 
ligands were known to interact with this domain, none of which affected the catalytic efficiency 
of thrombin.   
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A recent publication reported an exosite 2 ligand (F12 fragment) that shows preferred 
binding to the thrombin zymogen-like form. Increasing sodium concentration to the physiological 
level shifts thrombin to the proteinase (fast) form and dramatically decreases the binding of this 
ligand. Thrombin was shown to be almost 80% saturated with sodium under physiological 
conditions, which means that it is mostly found in the fast form in blood.77 Our lab has been 
working on developing allosteric direct inhibitors for thrombin that target exosite 2. The hypothesis 
that exosite 2 ligands prefer the slow form of thrombin would make those inhibitors clinically less 
relevant.  
To test this hypothesis, experiments were designed to assess FDSO3 affinity for thrombin 
under different sodium concentrations. This was done by directly measuring KD using surface 
plasmon resonance (SPR). Thrombin was fixed to a gold chip using a standard amine coupling 
technique. The calculated kinetic parameters are used to estimate the binding affinity according to 
the equation: 
ܭ஽ ൌ ௞೚೑೑௞೚೙ 	    (equation 12) 
A series of buffers with varying concentration of sodium chloride were used as the running 
buffer, keeping the ionic strength constant using choline chloride. This prevents the electrostatic 
interference arising from variation in the salt content and focuses on the structural consequences 
of varying sodium concentration. 
5.4.1. EXPERIMENTAL  
5.4.1.1. Proteins, LMWLs, Chemicals and Reagents.  
The sulfated dehydropolymers CDSO3 and FDSO3 were synthesized in two steps from 4-
hydroxycinnamic acid monomers, caffeic acid and ferulic acid, using chemo-enzymatic 
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synthesis.49 Mixed, self-assembled monolayer of alkanethiolates generated from the combination 
of polyethylene glycol-terminated alkanethiol (90%) and COOH-terminated alkanethiol (10%) 
slides were purchase from Reichert  Technologies (Buffalo, NY). Human α-thrombin was 
purchased from Haematologic Technologies (Essex Junction, VT). Stock solutions of thrombin 
were prepared in 10 mM sodium acetate buffer (pH 5.2). All other chemicals were analytical 
reagent grade from either Sigma Chemicals (St. Louis, MO) or Fisher (Pittsburgh, PA) and used 
as such.  
5.4.1.2. Measuring the Affinity of FDSO3 – Thrombin Interaction Using 
Surface Plasmon Resonance (SPR).  
The affinity of FDSO3 binding to thrombin was determined using 10 mM HEPES buffer 
(pH 7.4) containing 2.5 mM CaCl2, 0.1 % PEG 8,000 as the running buffer. Thrombin was attached 
to mixed, self-assembled monolayer sensor chips using a standard amine coupling technique. In 
the coupling process, the surface of the slide is initially activated by injecting a solution of 1-ethyl-
3-[3-dimethylaminopropyl]carbodiimide (EDC) and N-hydroxysuccinimide (NHS), mixed right 
before the injection, for 20 min at a flow rate of 10 μl/min. This was followed by injecting 100 μM 
thrombin at a flow rate of 10 μl/min for 20 min to load the enzyme on one channel only on the 
chip surface (sample channel). The loading was monitored by the increase in response unit that 
indicate thrombin attachment. The other channel was kept unchanged (reference channel). After 
loading thrombin, the remaining activated surface on the sample channel as well as the reference 
channel was treated twice with 1M ethanolamine (pH 8.5) for 20 min at 10 μl/min flow rate, 
repeating this step is essential to ensure blockage of the remaining active groups on the chip that 
can lead to non-specific binding. A serial dilution of FDSO3 (20 – 2,400 nM) was injected at a flow 
rate of 50 μl/min on the two channels of the loaded chip, each concentration was allowed 3 min 
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for association, this was followed by buffer flow for 6 min at 50 μl/min to allow dissociation. The 
surface of the slide was regenerated in-between the injections using 20 mM NaOH for 15 sec at 
50 μl/min. The reading from the reference chip as well as three blank injections were used to 
account for any non-specific binding or baseline drift. Data obtained was processed using Scrubber 
2 software®.       
5.4.2. RESULTS 
5.4.2.1. FDSO3 Binding and Inhibition Is Improved by Increasing Sodium 
Concentration. 
The study was performed in constant ionic strength buffers (0.2 M) to ensure the 
electrostatic component of FDSO3 binding will remain the same with varying Na+ concentration. 
As the concentration of sodium increased, there was a decrease in the KD, which indicates an 
improved affinity of binding (Figure 44, Table 15). The affinity increased from 49.2 nM to 1.29 
nM as sodium concentrations increased from 0 – 200 nM. The KD values were used as a signal to 
estimate the affinity of sodium binding to thrombin (Figure 45) using standard binding equation:  
݂ ൌ ܤఖ ൅ ஻೘ೌೣ	ሾே௔ሿ
శ
ሺ௄ವ	ା	ሾே௔ሿశሻ         (equation 13) 
The KD was calculated to be 1.9 ± 0.4 mM, which is in good agreement with the most recent 
published data of 4 mM.77 The data show clearly that, unlike the reported F12 fragment that binds 
at exosite 2, FDSO3 binding is improved with higher sodium concentrations. This essentially 
means that it binds preferentially to the “fast” proteinase thrombin, which is the prevalent and 
clinically relevant form. 
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5.4.3. DISCUSSION 
Unlike all known exosite 2 ligands, our molecules were shown to inhibit thrombin in a 
direct, antithrombin-independent manner. A recent study postulated that a series of species or 
conformations of thrombin exists between the activated proteinase-like and zymogen-like states.77 
Lower affinities were reported for an exosite 2 binding ligand (F12 fragment) when the sodium 
concentration was increased. To determine if increasing sodium concentrations will decrease the 
affinity of FDSO3, the KD was measured with increasing sodium concentrations using SPR.The 
ionic strength was kept constant at 0.2 M using complementary concentrations of choline chloride. 
As the sodium concentration increased in the running buffer, FDSO3 showed increased affinity for 
exosite 2. The affinity increased from 50 nM in absence of sodium to ~2 nM in presence of 0.2 M 
sodium (Table 15). This indicated that unlike the reported exosite 2 ligand, our molecules show 
preference for binding to the proteinase form of thrombin that prevails under physiological levels 
of sodium.  
Previous publications showed that energetic linkages exist between active site, sodium 
binding site and exosite 1. This work presents a proof that the energetic linkage between sodium 
binding site and exosite 2 is direct and effector-dependent. FDSO3 shows increased binding and 
inhibition with increased sodium concentration, unlike the F12 fragment reported to have lower 
affinity with sodium binding. The data offers a more comprehensive view of the allosteric network 
of thrombin, where signaling can be bidirectional and ligand dependent.  Na+ binding is needed 
for stabilizing the conformation of thrombin and our results show that this leads to better binding 
for exosite 2 ligands.   
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Table 15. The salt dependency of KD of FDSO3 was monitored by measuring the kA and kD 
using SPR in buffers of increasing sodium concentrations (0 – 200), ionic strength 
was kept constant using complementary concentrations of chloride. 
 
 
 
 
 
 
 
 
 
aKD was measured using Scrubber® software by fitting the association and dissociation rate constants 
obtained directly from SPR to equation 12 (see experimental section). 
  
[Na]+ (mM) [Choline]
+ 
(mM) FDSO3 KD (nM)
a 
200 0 1.29 
150 50 5.79 
50 150 7.32 
20 180 8.96 
7.5 192.5 11.4 
5 195 13.4 
3 197 24.2 
0 200 49.2 
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Figure Legends 
Figure 44. Binding isotherms for binding of FDSO3 to the immobilized thrombin using surface 
plasmon resonance. Increasing concentrations of FDSO3 (80, 160, 240, 320, 400 nM) 
were bound to thrombin at 25 °C in either 150 mM (black lines) or 5 mM (grey lines) 
of NaCl complemented by 50 or 195 mM choline chloride, respectively. Injections were 
done to allowing association (3 minutes) then buffer flowed for dissociation (6 
minutes). Scrubber software was used to calculate affinity based on a 1:1 binding 
model, fit is shown in thick lines versus thin lines for actual data. 
Figure 45. KD determined by SPR used as a signal to calculate the affinity of sodium binding to 
thrombin. Solid lines represent the regressional fit to equation 13 in which KD, Bο and 
Bmax were allowed to float.   
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5.5. CONCLUSION 
Dissecting the detailed interactions of polyelectrolytes with proteins has been established in 
literature as a substitute for structural data to obtain an insight about these complex structures. The 
study of the binding salt-dependency is an information rich method that indicates the number of 
ion-pairs formed between CDSO3 or FDSO3 and thrombin. The results corroborated the site-
directed mutagenesis data obtained for both molecules and indicated more ionic interactions 
formed between FDSO3 than CDSO3 and thrombin. The thermodynamic signature indicated that 
the two inhibitors had positive ΔCp similar to heparin. This highlights the fact that burial of the 
polar surface of exosite 2 during complex formation, combined with the electrostatic interactions 
involved are shared features between LMWLs and heparin despite their structural difference.  
The linkage between exosite 2 and thrombin was studied using FDSO3 binding to surface 
immobilized thrombin. This allows direct, label-free measuring of the effect that sodium binding 
has on the binding at exosite 2, without interference from active site involvement. The increased 
sodium concentration led to a conformational change in exosite 2 that directly affected the KD of 
FDSO3. This data shows for the first time a positive correlation between sodium binding and the 
affinity of an exosite 2 ligand and refutes the idea that the origin of inhibition is due to sodium 
displacement leading to formation of “slow” thrombin. 
Understanding how these complex polymers interact and inhibit thrombin on the molecular 
level is vital to the design of small molecule inhibitors bearing the same scaffold and recognition 
elements. This sheds new light on the control of allosteric signals in enzymes by adding another 
layer to the already complicated thrombin allostery.   
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Chapter 6: General Conclusion 
Sulfated low molecular weight lignins (LMWLs), CDSO3 and FDSO3, designed recently 
as macromolecular mimetics of heparin, were found to exhibit potent anticoagulant activity. Small 
molecules based on the same scaffold, SBD and SBT, showed promising thrombin inhibition. We 
were able to address the mechanism of the inhibition using Michaelis-Menten kinetics. All the 
molecules were found to be allosterically impairing thrombin activity using either noncompetitive 
or uncompetitive mechanism.  
Absence of competition with hirugen, an exosite 1 ligand, and competition with polymeric 
heparin points to exosite 2 as the site of interaction for these inhibitors. Yet mixed competition 
results with other exosite 2 ligands indicated that the molecules utilize different sub-sites within 
exosite 2 for interaction. Site-directed mutagenesis was used to pin point the key residues 
important for inhibition. All of all positively charged exosite 2 residues were mutated one at a time 
to alanine to abolish its charge. The data showed that Arg93 and Arg175 are the major residues 
involved in CDSO3 binding. FDSO3 showed a progressively greater defect in inhibition with 
double point mutations, the triple mutant Arg93,97,101Ala displayed a 50 fold drop in inhibition. 
A single mutant, Arg173Ala, displayed 22-fold reduction in IC50 of SBD, while Arg233Ala was 
the only mutation that impaired SBT inhibition. This proves the fact that in spite of the structural 
similarity between the two polymers and the two small molecules, the inhibitors do not share the 
same binding space in exosite 2.  
To understand the types of interactions involved in thrombin interaction with the polymers, 
we resorted to salt-dependence studies. This showed that CDSO3 had fewer ionic contacts with 
thrombin, with most of its binding energy derived from non-ionic interactions. FDSO3 on the other 
 
 
153 
 
hand had a balanced contribution of ionic and non-ionic forces. Thermodynamic studies showed 
that both polymers have a positive ΔCp of binding, which proves the involvement of electrostatic 
forces and signals the burial of the polar residues on thrombin exosite 2.  
These molecules offer a rare chance to study thrombin allostery. Little is known about the 
interplay between exosite 2, active site and sodium binding site. The allosteric nature of inhibition 
indicated that, for the first time, a link is proven to exist between exosite 2 and the active site that 
could be used to inhibit the enzyme. The presence of sodium was found to enhance the binding of 
FDSO3 at exosite 2, which establish the energetic coupling between exosite 2 and sodium binding 
site. The results identify novel binding sub-sites within exosite 2 that are energetically coupled to 
thrombin’s catalytic function and linked to the sodium binding site. The design of high affinity 
small molecules based on LMWLs scaffold presents major opportunities for developing clinically 
relevant, allosteric modulators of thrombin. 
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APPENDIX A 
Abbreviations Used 
AT: antithrombin 
DTIs: direct thrombin inhibitors 
fFPR-Th: fluorescein labeled inhibited thrombin 
FibP: γ’ fibrinogen pepƟde 
GAGs: glycosaminoglycans 
H8: heparin‐derived octasaccharide  
HirP: hirugen pepƟde 
LMWHs: low molecular weight heparins 
LMWLs: low molecular weight lignins 
PARs: protease‐acƟvated receptors 
SBD: sulfated benzofuran dimer 
SBT: sulfated benzofuran trimer 
Serpin: serine protease inhibitor 
SPR: surface plasmon resonance 
UFH: unfracƟonated heparin 
VKAs: vitamin K antagonists  
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